AU2001259637A1 - Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use - Google Patents
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of useInfo
- Publication number
- AU2001259637A1 AU2001259637A1 AU2001259637A AU5963701A AU2001259637A1 AU 2001259637 A1 AU2001259637 A1 AU 2001259637A1 AU 2001259637 A AU2001259637 A AU 2001259637A AU 5963701 A AU5963701 A AU 5963701A AU 2001259637 A1 AU2001259637 A1 AU 2001259637A1
- Authority
- AU
- Australia
- Prior art keywords
- microparticle
- metal ion
- lipid
- drug
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
Description
STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
Field of the Invention This invention relates to powdered pharmaceutical compositions for drug delivery that exhibit improved stability and dispersability over the shelf life of the composition. More particularly, this invention relates to a highly stable metal ion-lipid microparticle for drug delivery. Background of the Invention Powder formulations are the mainstay of drug delivery. Pharmaceutical powders are normally formulated as suspensions, dry powders, tablets, powders for reconstitution and capsules. Pharmaceutical powders are used to facilitate drug delivery because of their ease of use and increase in stability of the active ingredient. However, in the last few years, strict control measures by the FDA and other agencies as to dose uniformity, stability and the prohibition of use of commonly used excipients have threatened certain powder products that are currently on the market. Consequently, this has resulted in greater difficulties in compounding successful powder formulations. Optimization and control of flow and dispersion characteristics of a powder formulation are of critical importance in the development of powder products and, in particular, powder inhalation products. These characteristics are a function of the principal adhesive forces between particles such as van der waals forces, electrostatic forces and the respective surface tensions of absorbed liquid layers. These forces are influenced by several fundamental physicochemical properties including particle density and size distribution, particle morphology (shape, habit, surface roughness) and surface composition (including absorbed moisture). Interparticle forces that influence flow and dispersion properties are particularly dominant in the micronized or microcrystalline powders that are required for inhalation. Attempts to overcome these forces such as blending a drug with a carrier and adding excipients have been made but have met with limited success. For example, blending a drug with a carrier provides some advantages such as increasing the bulk of the formulation which allows for easier metering of small quantities of potent drugs either at the manufacturing stage or within a delivery device such as a reservoir type device. However, significant disadvantages are evident such as drug/excipient segregation, which severely impacts the dosing and the shelf-life of the composition.
Another approach in drug delivery that has been investigated widely is the incorporation of a drug with excipients by freeze-drying or spray drying. Spray drying is commonly used in the pharmaceutical industry for various substances such as antibiotics, vitamins, vaccines, enzymes, plasma and other excipients as well as for preparation of microcapsules and slow release formulations. Spray drying has gained interest due to the technique's simplicity, low cost, versatility and overall effectiveness. Spray drying is sometimes regarded as a harsh method when compared to freeze-drying due to the high temperature of the drying gas which can be detrimental to sensitive biological materials. However, when considering the spray drying process in greater detail, it is evident that the spray droplets and the dried powder particles maintain a temperature well below the inlet temperature of the drying gas throughout the
entire process. As long as water is evaporated from the droplets, a cooling effect is achieved thereby preventing exposure of the product to high temperatures.
Millqvist-Fureby (Int. J. Pharm. ,1999,188, 243-253) has shown the advantages of spray drying trypsin versus freeze-drying where it was demonstrated that the activity loss of trypsin was reduced when it was spray dried instead of freeze-dried. This was explained by the "vitrification" hypothesis which states that it is essential to maintain an excipient in an amorphous or "glassy" state to prevent the protein from changing its shape due to the rigidity of the matrix (Franks, 1991, Biopharma 4, 38-55). These findings, particularly regarding the effect of carbohydrates (most of which tend to crystallize when frozen) and the fact that surface active components experience physical changes in the drying process, which in the case of certain compounds (proteins) are detrimental to functionality of that compound (i.e. activity loss of the protein), show the advantages of spray drying.
Those skilled in the art know that powders have a tendency to be amorphous by nature and that amorphous structures are not stable. Amorphous forms of many drugs and excipients can be produced during processing and revert to the thermodynamically stable crystalline form on storage. The amorphous form will have different physical properties and as such will interact with other phases (i.e. other formulation components, whether these are powders or liquids) in a different manner than that of the crystalline form. An additional complication in systems that contain amorphous material is that the amorphous structure can change under varying conditions and may collapse when exposed to humid air. It has also been known for many years that amorphous materials can collapse when above their glass transition temperature due to the inability of the rubbery material to support its own weight under gravity. For example, lactose is a commonly used excipient which in its amorphous state (micronization, spray drying, freeze- drying, etc.) exhibits varying degrees of structural collapse when held at 50% relative humidity ("RH"). Buckton (1995 Int. J. Pharm. 123, 265-271) noted that water was rapidly absorbed and desorbed by a structure prior to collapse but water sorption to and from the collapsed structure was slow and controlled by diffusion in the solid, rather than just by external relative humidity.
The presence of water in amorpous materials is of importance for two principal reasons. The first reason is called the amplification process (Ahlneck, 1990 Int. J. Pharm., 62,87-95) which states that a sample containing 0.5% amorphous material and 0.5% associated water will in reality have most of the water absorbed in the amorphous region. If this amorphous excipient material is responsible for maintaining the integrity and the structure of the particle, the physical and chemical stability of the product will be in jeopardy. The second reason water is important is the retention of water in amorphous regions of the sample. Water that is absorbed in a non-collapsed amorphous structure will desorb rapidly and be easily dried; however, if the water is in a collapsed region, this will not hold true and the water will only be able to be removed slowly by diffusion through that region. Once the structure has collapsed, even if the powder is dried, the powder has gone through irreversible transformations that will compromise the integrity of the powder. Thus, water is recognized to be the enemy in the performance and in the physical and chemical stability of most drug formulations including dry powders.
Another important consideration as to the presence of water is the characterization of the effects of sorbed water with glassy drug formulation on the glass transition temperature ("Tg"). The relationship between water content and Tg has been explored in a number of publications in the pharmaceutical literature (e.g., Hancock, 1994 Pharm. Res. 11,471-477). The presence of water is known to lower the T9 of amorphous systems and it has been well established that the presence of water will plasticize the host material leading to a high probability of physical and chemical instability. Aπdoris (1998 Pharm. Res. 15, 835-842) and Hancock (1997, J Pham, Sci. 86, 1-12) have addressed the issue of the relationship between storage temperature and the crystallization of amorphous material. These authors have suggested that as long as amorphous materials are stored at approximately 50°C below their Tg , the amorphous materials should be both physically and chemically stable since molecular mobility will be reduced. The extent of the depression of Tg can be related to the weight fraction of sorbed water. The relationship between moisture uptake and Tg may be described in terms of the Gordon-Taylor relationship (Gordon, 1952 , J. Appl. Chem. 2, 493-500). Assuming perfect volume additivity with no specific interaction between the components, the glass transition of the mixture, T„ , is given by the following formula: amix
[1]
where φ is the volume fraction and the subscripts represent the two components. Redefining the equation in terms of weight fractions, the formula is:
_ (w Tgl)+(Kw2Tg2) βmix wl+Kw2 [2]
where w and w2 are the weight fractions of water and drug respectively and K can be considered to be the ratio of the free volumes of the two components. The Tg of water has been published to be 135 °K (Sugisaki 1968, Bull.
Chem. Soc. Jpπ. 41, 2591-2599) with a K value of 0.198.
Even relatively small amounts of water might be detrimental to the stability of amorphous materials which leads to the question of how much water is necessary to lower the Tg to below the storage temperature, thereby considerably increasing the risk of product failure. The amount of water necessary to lower the Tg to below the storage temperature can be estimated by considering the Simha-Boyer rule:
K = -^ [3]
where p, and p2 are the densities of materials one and two respectively and Tgl and Tg2 are the glass transition temperatures of materials one and two respectively (Simha, J. Chem. Phys. 1962, 37, 1003-1007).
Royall ( Int. J. Pharm. 1999, 192, 39-46) derived an equation that estimates the critical moisture content (JVC) which would result in the value of Tg falling to a value 50 °K above the storage temperature, thereby providing a much greater margin of safety with regard to the possibility of collapsed structures:
[4]
where Tsτ is the storage temperature and Tg2 is the transition temperature of the dry mixture and p1 and p2 are the densities of materials one and two respectively.
The use of lipids (e.g., free fatty acids and their salts as well as phospholipids) in powder formulations is well accepted in the pharmaceutical industry due to lipids' biotolerability and their physical and chemical characteristics. Polar head groups and surface area of lipids play a functional role at different molecular levels in the context of metal ion-lipid binding. The surface area per lipid molecule together with its electrical charge determines the membrane surface potential ψ„. The electrical charge of the lipid molecule regulates the attraction or repulsion of cations at the lipid-water interface.
The tendency of metal ions to form several coordination bonds with phospholipid head groups can reduce the distance between head groups, thus stretching the hydrocarbon chains into an all-trans conformation. A hydrocarbon chain in the all-trans conformation has a cross-section of approximately 24 A2, thus yielding a minimum area of about 48A2 for a crystalline phospholipid with two hydrocarbon chains. The "crystallization" phenomenon induced by the cation will reduce molecular mobility which is the cause of instability for certain formulations. In the absence of organization by metal cations, the hydrocarbon chains are disordered, with a direct consequence of lateral expansion of the lipid membrane. In the liquid-crystalline state, the average cross-sectional area for this lipid increases to about 60 A2 (Bϋldt, 1979, J. Mol. Biol., 134, 673).
The increase in the chain-melting transition ("crystallization") temperature may exceed 50°C if the interfacially bound ions have displaced most of the water from the interface. Essentially, anhydrous lipid-ion complexes in excess solution are no exception. One example of this are multivalent metal-ion complexes of diacylphosphatidylserine bilayers (Hauser, 1981, Biochemistry, 23, 34-41). These bilayers form highly ordered, essentially water free bilayers with extremely high transition temperatures in the range between 151-155 °C.
However, the highest chain-melting phase transition temperatures for diacylphospholipid membranes with monovalent ions or protons bound to the headgroup do not exceed 100°C due to the lack of strong intermolecular ionic coupling.
Ion-induced phase transition shifts can move in either direction. When a membrane-ion complex binds water more strongly than the membrane surface without bound ions, the ion-induced shift of the biiayer main transition temperature is downwards. This is the case with phosphatidylcholine in the presence of anions or with
phosphatidylserine with bound organic counter ions. The chain-melting phase transition temperature for such systems therefore decreases with the increasing bulk electrolyte concentration.
Phospholipid affinity for cations generally follows the sequence:
Lanthanides > transition metals > alkaline earth metals > alkali metals
It is an object of the present invention to provide powdered pharmaceutical compositions for drug delivery that exhibit improved stability and dispersability over the shelf life of the compositions. It is a further object of the invention to avoid the usage of excipients that will reduce the shelf-life of the compositions. It is a further object of the invention to incorporate the drug or active ingredient with the particle avoiding active compound segregation. It is a further object of the invention to provide a novel drug delivery system that is capable of maintaining a high level of dispersability over time.
Summary of the Invention
The present invention is directed to stable, dry metal ion-lipid microparticle compositions for drug delivery and processes and methods of making the same. The technology is based on the formation of a lipid-metal ion complex matrix that incorporates the drug or active agent to be delivered. The stabilized- particulates or microparticles of the present invention have a lipid concentration of 25-98% w/w, a drug or active agent concentration from 0-80% w/w and the metal ion to lipid is greater than 0-2. The present invention is also directed to stable powdered metal ion-lipid pharmaceutical compositions wherein the compositions have a transition temperature ("Tm") of at least 20° C above the recommended storage temperature ("Tsτ") for drugs and exhibit improved stability and dispersability over the shelf-life of the composition. The present invention is also directed to methods of treating certain diseases or conditions by the therapeutic administration of the microparticle compositions of the present invention.
The present invention is based on the principle that by complexing lipids with metal cations it is possible to substantially change the structure of the lipid by increasing its ordering and by dehydration of the lipid headgroups. This results in a significantly more stable compound which is less susceptible to humidity upon storage than typical spray dried lipid and drug combinations. The physical and chemical stability of the microparticle of the present invention is increased by reducing the disorder in the lipid which consequently reduces the molecular mobility that is the main cause of physical and chemical instability. It is known that amorphous materials (produced by spray drying, icronization, freeze-drying) are unstable and have a tendency to absorb water in order to form much more stable structures (i.e. crystals). Unfortunately, water acts as a plasticizing agent, thereby reducing the glass transition temperature of the powder, increasing the molecular mobility and increasing kinetic processes such as nucleation and crystallization. The resulting low viscosity environments prompt chemical reactions that facilitate chemical degradation.
The increase in stability of the microparticle of the present invention is due to the strong affinity that some metal ions have for lipids. A lipid - metal ion complex will result when the lipids interact with the metal ion. This
interaction is known to reduce the distance between the lipid headgroups and, as a consequence, reduce water uptake that is the main cause of dry powder instability. The microparticles of the present invention have shown surprisingly high stability against water sorption when compared to other spray dried formulations.
The process and composition of the present invention involve the formation of a lipid-cation complex (in the form of a solution, micelle, liposome suspension or an emulsion) and a drug or therapeutically or biologically active agent or compound incorporated in the metal ion - lipid complex. By "incorporated", it is intended to mean a combination of the metal ion lipid complex with the drug or active agent to form one unit. The drug or active agent can be engulfed within the metal ion - lipid complex or can predominantly occur on the surface of the composition. Further, incorporation can mean that the drug or active agent can be present as a solution, suspension or solubiiized by the lipid. The incorporation process can be achieved by freeze-drying, flash evaporation and most preferably by spray drying. The invention also includes the use of lipids that are generally regarded as safe such as phospholipids and free fatty acid salts. It is also important to understand that the drug or active agent can be a metal or lipid-metal ion complex in some instances.
Those skilled in the art will appreciate the increase in stability of the microparticle compositions which is achieved in part by forming the entire particle structure with only one material, which is the lipid-metal ion complex. This material exhibits improved physical and chemical properties in contrast to the commonly used small molecules (e.g. lactose, sucrose, etc.) that when amorphous, are susceptible to moisture and consequently, instability. The microparticles of the present invention have shown surprisingly high dispersion stability in perfluorooctyl bromide (PFOB) and in the non-CFC hydrofluoroalkane propellant HFA 134a that has been approved for medical use. The lyophilic nature (characterized by strong attraction between the colloid medium and the dispersion medium of a colloid system) of the particle components is responsible for the dispersion stability in such non-aqueous media, in addition to the reduced adsorbed water on the particles surface, due in part to the non-hygroscopic nature of the metal ion - lipid complex.
Various metal ions may be used in the metal ion-lipid complex of the present invention such as calcium, magnesium, aluminum, zinc and iron in combination with a salting ion. The metal ion used in the formation of the metal ion-lipid complex includes any metal chosen from lanthanides, transition metals, alkaline earth metals and further including lithium and non-toxic metal ions or any metal ion at non-toxic levels from groups lla, lllb and mixtures thereof and all metals from atomic numbers 21 • 30; 39 - 48, 57 - 80 and 89-106. It is also within the scope of the present invention to use a metal containing ion such as V0+2. It is also possible to use organic ions or compounds that form dehydrating complexes with phospholipids.
Also included within the scope of the invention are the use of radioisotopes in combination with salting ions such as chloride, nitrates and others. The condition is that the metal ion salt must be able to dissolve in a suitable media in order to interact with the lipid, which depends on the salt.
The metal ion-lipid combination of the present invention may be comprised of a single lipid or can be mixed with other surfactants to obtain the desired characteristics. Some of the surfactants that can be used are
ethoxylated sorbitan esters, sorbitan esters, fatty acid salts, sugar esters, phospholipids, pluronics, tetronics, ethylene oxides, butylene oxides, propylene oxides, cationic surfactants, polyoxyalkylene block copolymers of the formula Y[(A)„-E-H]„ where A is a polyoxyalkylene moiety, x is at least 2 and Y is derived from water or an organic compound containing x reactive hydrogen atoms, E is a polyoxyethylene moiety, and n can be from 5 to 500. Other classes of surfactants which may be used with the present invention include phosphatidylcholines, egg phosphatides, soy phosphatides, phosphatidylethanolamines, phosphatidylserines, phosphatidylinositols cardiolipin, polymerizable phospholipids, lyso-phosphatidylcholines, lysophosphatides, D-erythro-sphingosines, sphingomyelins, ceramides, cerebrosides, platelet-activation factor (PAF) [Ether ester analogs of phosphatidylcholines], acyl PAF analogs, hydrogenated phospholipids, krill phosphatides, phosphatidic acids, phosphatidylglγcerols, phospholipids with multifarious head groups (phosphatidylmethanol, phosphatidylethanol, phosphatidylpropanol, phosphatidylbutanol, etc.), dibromo phosphatidylcholines, mono and diphytanoyl phosphatides, mono and diacetylenic phosphatides, PEG phosphatides, a phipathic antigens phosphatides, mono and diacyl glycerols, mono and diacyl ethylene glycols, mono and diacyl sorbitols, mono and diacyl glycerol succinates, alkyl acyl phosphatides, free fatty acids and salts, fatty alcohols, fatty amines and their salts, fatty ethers, fatty esters, fatty amides, fatty carbonates, cholesterol, cholesterol esters, cholesterol amides and cholesterol ethers.
Other surfactants which may be used are shown in the tables below:
Anionic or Cationic Surfactants Listed in Different Pharmacopoeia or Extra Pharmacopoeia
Surfactants Class Pharmacopoeia/extra phi irmacopoeia
Aluminium monostearate Anionic USP/NF Martindale
Ammonium lauryl sulfate Anionic Martindale
Calcium stearate Anionic USP/NF Eur. Ph. BP Martindale
Dioctyl calcium sulfosuccinate Anionic Martindale
Dioctyl potassium sulfosuccinate Anionic Martindale
Diotctyl sodium sulfosuccinate Anionic USP/NF BP Martindale
Emulsifying wax Anionic Eur. Ph. BP Martindale
Magnesium lauryl sulfate Anionic Martindale
Magnesium stearate Anionic USP/NF Eur. Ph. BP Martindale
Mono-, di-, triethanolamine lauryl sulfate Anionic Martindale
Potassium oleate Anionic Martindale
Sodium castor oil Anionic Martindale
Sodium cetostearyl sulfate Anionic Eur. Ph. BP Martindale
Sodium lauryl ether sulfate Anionic Martindale
Sodium lauryl sulfate Anionic USP/NF Eur. Ph. Martindale
Sodium lauryl sulfoacetate Anionic Martindale
Sodium oleate Anionic Martindale
Sodium stearate Anionic USP/NF Martindale
Sodium stearyl fu arate Anionic USP/NF Martindale
Sodium tetradecyl sulfate Anionic BP Martindale
Zinc oleate Anionic Martindale
Zinc stearate Anionic USP/NF Eur. Ph. Martindale
Benzalconiu chloride Cationic USP/NF Eur. Ph. Martindale
Cetrimide Cationic Eur. Ph. BP Martindale
Cetrimonium bromide Cationic BP Martindale
Cetylpyridinium chloride Cationic USP/NF Eur. Ph. BP Martindale
Nonionic Surfactants Listed in Different Pharmacopoeia or Extra Pharmacopoeia
Surfactants Pharmacopoeia/extra pharmacopoeia
Polyols esters
Glyceryl monostearate USP/NF Eur. Ph. BP Martindale
Monodiglyceride USP/NF Eur. Ph. Martindale
Glyceryl monooleate Martindale
Glyceryl behenate USP/NF Martindale
Sorbitan monolaurate USP/NF Eur. Ph. BP Martindale
Sorbitan monopalmitate USP/NF Eur. Ph. Martindale
Sorbitan monooleate USP/NF Eur. Ph. BP Martindale
Sorbitan monostearate USP/NF Eur. Ph. BP Martindale
Sorbitan sesquioleate USP/NF Martindale
Sorbitan trioleate USP/NF Eur. Ph. Martindale
Sorbitan tristearate Martindale
Polysorbate-20 USP/NF Eur. Ph. BP Martindale
Polysorbate-40 USP/NF Martindale
Polysorbate-60 USP/NF Eur. Ph. BP Martindale
Polysorbate-65 Martindale
Polysorbate-80 USP/NF Eur. Ph. BP Martindale
Polysorbate-85 Martindale
Diethylene glycol monostearate Martindale
Ethylene glycol monostearte Eur. Ph. Martindale
Propylene glycol monostearte USP/NF Eur. Ph. Martindale
Self-emulsifying glyceryl stearate BP
Emulsifying wax NF USP/NF
Polyoxyethylene esters and ethers
PEG-40 stearate USP/NF* Eur. Ph. Martindale
PEG-50 stearate USP/NF* Eur. Ph. Martindale
PEG-8 stearate USP/NF* Eur. Ph. Martindale
Polyoxyl-35 castor oil USP/NF* Eur. Ph. Martindale
Polyoxyl-40 hydrogeneated castor oil USP/NF Martindale
Laureth-2 Eur. Ph. Martindale
Laureth-4 Eur. Ph. Martindale
Laureth-9 Eur. Ph. Martindale
Ceteareth-20 Eur. Ph. Martindale
Steareth-20 Eur. Ph. Martindale
Oleth-10 USP/NF* Eur. Ph. Martindale
Poloxamers
Poloxamer-188 USP/NF BP Martindale
Poloxamer-407 USP/NF Martindale
Other nonionic surfactants
Nonoxinols-9 USP/NF Martindale
Nonoxinols-10 USP/NF* Martindale
Nonoxinols-11 Martindale
Propylene glycol diacetate USP/NF* Martindale
Polyvinyl alcohol USP/NF Martindale
USP/NF* : present in USP 23/NF 18 but not in USP 24/NF 19.
The microparticles of the present invention have numerous therapeutic applications in drug delivery. For example, lung surfactant deficient neonates are also known to be calcium deficient and calcium is required for the
formation of the "myelin" structures that are required for normal breathing. The administration of a specific metal ion-lipid combination such as Ca-dipalmitoyl phosphatidylcholine ("DPPC") to a neonate using any of the available techniques (nebulization, insufflation, dry powder inhalation, instillation, etc.) will deliver the lipid in the "right" structure and at the same time function as a supply of calcium. Other therapeutic uses for the metal ion - lipid microparticle of the present invention would include use with tobramycin for treating pneumonia, use with ethambutol as a tuberculostatic agent, use in combination with compounds from the sulfonamide family for inhibiting cell metabolism, use for delivery of therapeutic gases, use in combination with antibiotics from the penicillin and cephalosporin family for inhibition of bacterial cell wall synthesis, use in combination with antibiotics of the polymixin and tyrothricin family for interacting with plasma membranes, use with rifamycins, aminoglycosides, tetracyclines and chlorapenicols for disruption of protein synthesis and use in combination with the nalidixic and proflavine antibiotic families for inhibition of nucleic acid transcription and replication. The metal ion - lipid combination of the present invention can also be used in combination with drugs acting on DNA such as actinomycin D, chloroquine and quinine for intercalating cytostatic agents, used in combination with drugs from the mustard family and cis-platin and used in combination with bleomycin for use as a DNA chain cutter.
Other drug or active agents that may be used with the present invention are shown in the table below: Some Typical Applications of Pharmaceutical Suspensions
Therapeutic effect Active copmounds Typical concentration (mg/mL)
Antifungal Ketoconzole 20 Antihelminthic Pirantel pamoate 50
Tiabenzole 60
Anxiolytic Diazepam 0.5 Calcium antagonist Nicardipine 20 Antacid Almagate 130
Aluminum hydroxide 70
Magnesium hydroxide 200
Antianemic Folic acid 10
Ferrous gluceptate 30 Antibacterial Nalidixic acid 125
Amoxicillin 50
Ampicillin 50
Cefalexin 50
Cefradoxyl 50
Chloramphenicol palmitate 25
Nitrofurantoin 10
Antiepileptic Diphenylhydantoin 25 Cough relief Codeine 6
Dextromethorfane 0.5
Anti-inflammatory Ibuprofen 20
Antiviral Acyclovir 80
Nasal congestion relief Phenylpropaπolamine 3 fmmunological estimulation Palmidrole 100
Intestine motility estimulation Cinitapride 1
Intestine motility inhibition Albumin tannate 50
Delivery within the body of certain non-radioactive metals with therapeutic value, such as iron, copper, lithium and certain oligoelements may be accomplished by use of the microparticles of the present invention. The following radioisotopes may also be used in conjunction with the lipid or the lipid-metal ion complex for the medical purposes indicated below:
Radio-isotope Symbol Half-life Use
Thallium-201 TI-201 3 days Diagnostics
Gallium-67 Ga-67 3.26 days Diagnostics lndium-11 1 ln-111 2.8 days Diagnostics
Iodine- 123 1-123 13 hours Diagnostics
Palladium-103 Pd-103 17 days Diagnostics & Therapeutics
Molybdenum-99 Mo-99 2.7 days Diagnostics
Xenon-133 Xe-133 5.3 hours Diagnostics & Therapeutics lodine-131 1-131 8 days Diagnostics & Therapeutics
Iodine- 125 1-125 59.4 days Therapeutics
Fluorine-18 F-18 110 Minutes Diagnostics
Radioisotope Symbol Use
Germanium-68 Ge-68 Antibody labeling
Cobalt-57 Co-57 Instrument calibration
Zinc-65 Zn-65 Biochemistry
Strontium-85 Sr-85 Bone tracer
Phosphorus-32 P-32 Bone cancer therapy
Sulfur-35 S-35 DNA labeling
Yttrium-90 Y-90 Radioimmunotherapy
Samarium-153 Sm-153 Bone cancer therapy
Gadolinium- 153 Gd-153 Osteoporosis/ Diagnostic
Ytterbium-169 Yb-169 Radiography
Chromium-51 Cr-51 Blood volume
Maganese-54 Mn-54 Liver diagnostics
Selenium-75 Se-75 Biochemistry
Tin-113 Sn-113 Colon cancer therapy '
The powdered formulations described in the present invention can be applied to inhalation therapies, powders for reconstitution, dry powders and suspensions due to their unique powder stability. By inhalation therapies, we include but are not limited to techniques such as nebulization, insufflation, dry powder inhalation and aerosol inhalation including metered dose inhalers. Administration can include but is not limited to respiratory, pulmonary, otic, anal, optic, vaginal, intramuscular, intravenous, intratracheal, intracuticular, intraperitoneal, nasal, pharyngeal, sinal, subcutaneous, extradural, intracisternal, intrapleural and intrathecal delivery.
The characteristics of the present invention can be modified by using well known compounds described in the literature to modify release kinetics, act as stabilizers or to provide certain surface properties that may be required for specific applications. Examples of such compounds include: polysaccharides; polyvinylpyrrolidone; polyvinyl alcohol; polyethylene glycol; poloxamer block polymers; poloxamines; tetronics; cellulose esters; cellulose ethers; carboxymethylcellulose; hydroxymethylcellulose; carbopol; polyacrylic acids (and salts); crosslinked polyacrylic acids; polylactides; polyglycolides; starches; methylated starches; ethylated starches; crosslinked starches; inulin; dextrins; dextrans; dextran sulfates; cyclodextrins; peptides; polylysine; polyarginine; polyalaninine; polyglycine; and proteins e.g., albumins ( bovine, milk, human, egg). Particle morphology can also be manipulated by spray drying conditions, as well as by the ingredients used in the manufacturing of these powdered formulations. It is well known that in order for a powdered formulation to exhibit good suspension characteristics in a hydrophobic medium (e.g., air, CFC, HFC, PFC), the powder's surface has to be lyophilic (which means that the surface of the particle is able to interact with the suspension media). The stability results from the fact that the lyophilic surface interacts with the suspension media and is thermodynamically stable. Surfactants are known to interact with chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluoroalkanes and to a lesser degree with perfluorocarbons. T his interaction is somewhat dictated by the polarizability differences of the suspension media and the components on the surface of the particle. Since surface active compounds tend to reside on the surface of the particles (some drugs or actives also display surface activity that could destabilize the suspension by making the surface lyophobic), the stability of the suspension will be governed by the components on the surface. The use of surfactants in the form of the metal ion - lipid complex as the main building block (in contrast to small molecules that are lyophobic, like lactose) improves the suspension quality of the composition and decreases the susceptibility of the compositions to "melt" when exposed to relatively high moisture environments.
The other contributing factor that affects suspension stability is described by Stokes Law, an equation relating the terminal settling velocity of a sphere in a viscous fluid of known density and viscosity to the diameter of the sphere when subjected to a known force field:
v = 2 Jd - d2) 9μ [5]
where V = velocity of fall (cm s'1), g = acceleration of gravity (cm sec'2), r = "equivalent" radius of particle (cm), d, = density of particle (g ml1 ), d2 = density of medium (g mL"1), and μ = viscosity of medium (g cm"1 s'1). By using metal ion-lipid complexes with densities (measured by He displacement) ranging from 0.5 to 2.0 g cm'3, suspension stabilization by density matching will occur in most of the commonly used non-aqueous suspension media. This reduces the speed of sedimentation or creaming of the suspended powder.
The particle inertia of the powdered compositions described in the present invention is low since the density of the lipids used for the building block of the particle is small in comparison to salts. Low inertia means less force to "move" the particles, which will have an impact on their aerodynamic properties.
These particles have shown little particle-particle interaction (in part attributed to the low tendency of the metal ion-lipid to adsorb water), resulting in greater deaggregation when suspending in air or a meter dose inhaler ("MDI") propellant and improved flowability of the powder during processing and in dosing devices.
Advantages of the metal ion - lipid microparticles of the present invention over other spray dried formulations include: a) Ease of manufacturing - the microparticles of the present invention are produced by a combination of phospholipid dispersions, metal ion solutions and drug preparation followed by spray drying which is a well established pharmaceutical process which is known for its simplicity and versatility; b) The microparticles of the present invention are produced without the need of the formation of an emulsion or the use of an oil as a blowing agent. This is a significant improvement as to the cost of the final product. Any residual blowing agent in a microparticle could be a source of problems curtailing the release and approval of the product; c) The microparticles of the present invention are produced without the need of wall-forming agents in contrast to other types of microparticles. Typical spray dried wall forming agents (e.g., lactose, sucrose, mannitol etc.) are very hygroscopic which promotes physical and chemical changes which can render the product useless; d) The metal ion - lipid complex in the microparticles of the present invention act as a wall forming agent and are non-hygroscopic, making them ideal for inhalable formulations. Since these complexes act as a wall forming agent and are non-hygroscopic, they protect the product against the adverse effects of water; e) All preferred materials used in the manufacturing of the microparticles of the present invention are generally regarded as safe (GRAS); f) Due to the versatility in the process and powder characteristic's, a large number of drugs and other material can be incorporated, including heat sensitive proteins and other agents; and, g) No heating is required to eliminate residual solvents or blowing agents which is a step required in other spray dried formulations that use blowing agents. Heating the final product can cause irreversible damage to the active ingredients and to the powdered formulation itself.
Brief Description of the Drawings
Figure 1 is an electron microscopy image of one of the metal ion-phospholipid microparticles of the present invention;
Figure 2 shows the relationship between the storage temperature and the water content for a sample having a Tg of 80°C and a sample having a Tg of 120°C and shows that a content of 10% water will reduce the Tg from 80 to 20°C and 120 to 50°C;
Figure 3 shows the effects of high stress conditions (40° C/75% RH) on pMDIs where sample 6 has the negative effects of the counter-ions that will compete with the metal-lipid complex;
Figure 4 shows the theoretical relationship between the critical water content (%) calculated from Figure 4 at which Tg is lowered to the storage temperature as a function of "dry" Tg at a storage temperature of 40°C for the two different formulations.
Figures 5A - 5B illustrate Scanning Electron Microscopy images of Sample 8 discussed in Example 10 and shows the high surface area and the cavities on the particles surface; and,
Figures 6A - 6B illustrate Scanning Electron Microscopy images of Sample 9 discussed in Example 10 which show the differences in surface areas of Samples 8 and 9 and the absence of large cavities in Sample 9. Detailed Description of the Invention
The stable dry pharmaceutical composition of the present invention is preferably a dry powder comprised of microparticles that will exhibit a Tm of at least 20° above the recommended Tsτ.. The dry powder could be used for but not limited to the preparation of non-aqueous suspensions, powder for reconstitution, dry powders for inhalation, tableting, capsules, ointments, suppositories, creams, and shampoos. The stable powdered composition of the present invention is mainly made of a metal ion-lipid complex, where the lipid component could be a single lipid or a mixture of several lipids. The preferred lipids are, but are not limited to, phospholipids. The metal can be substituted with a stable or unstable radioisotope, or the radioisotope added in addition to the metal ion - lipid complex, including such radioisotopes as Tc -93, Tc -94 ,Tc -95, Thallium-201, Gallium-67, Ga-67, lndium-111, lodine-123, Palladium-103, Molybdenum-99, lodine-131, lodine-125, Fluorine-18, Germanium-68, Cobalt-57, Zinc-65, Strontium-85, Phosphorus-32, Sulfur-35, Yttrium-90, Samarium-153, Gadolinium-153, Ytterbium- 169, Chromium-51, Maganese-54, Selenium-75 and Tin-113. The metal ion or radioisotope can be chosen depending upon the application.
The stable dry pharmaceutical composition of the present invention can be manufactured by freeze-drying, flash evaporation, grinding and micronizing and most preferably by spray drying. The process involves the formation of a lipid-cation complex (in the form of a solution, micelle, liposome or an emulsion) and a drug or active compound incorporated with the lipid-cation matrix. The drug or active agent may be chosen from the group comprised of antiallergics, antifungals, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, monoclonal antibodies, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, lectin, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides, insulin, albumin, enzymes, genetic material (e.g., DNA, RNA and fragments thereof) pulmozyme, immunoglobulins and combinations thereof. Some specific drugs or active agents include albuterol, albuterol chloride, budesonide, fluticasone propionate, salmeterol xinafoate, formoterol fumarate, nicotine chloride, nicotine nitrate, triamcinolone acetonide, dexamethasone, beclomethasone dipropionate, genta icin, gentamicin chloride, gentamicin sulfate, ciprofloxacin hydrochloride, Taxol, amphotericin, amikacin, amikacin chloride, Tobramycin, Tobramycin chloride, Tobramycin nitrate.
Although not required for the production of this invention, the use of conventional additives or other ingredients could improve the properties of the powdered formulation is contemplated. Some of these properties are, but are not limited to:
1) Color, taste and appearance by use of colorants and flavorings; 2) Release kinetic modifiers of the particle by use of disintegrants, poloxamers, polysaccharides, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, PLURONIC block polymers, tyloxapol, poloxamers, poloxamines, tetronics, cellulose esters, cellulose ethers, carboxymethylcellulose, hydroxymethylcellulose, carpools, polyacrylic acids (and salts), crosslinked polyacrylic acids, polylactides, polyglycolides, starches, cyclodextrins, methylated starches, ethylated starches, crosslinked starches, inulin, dextrans, dextran sulfates, polyoxyalkylene block copolymers of the formula Y[(A)„-E-H]X where A is a polyoxyalkylene moiety, x is at least 2,
Y is derived from water or an organic compound containing x reactive hydrogen atoms, E is a polyoxyethylene moiety and n can be from 5 to 500; 3) Peptides, polylysine, polyarginine, polyalanine, polyglycine and proteins such as albumins (e.g., bovine, milk, human, egg), and fatty acid metal salts; 4) Compounds affecting particle morphology and properties are plasticizers, wetting agents and vitrifiers;
5) Preservatives including antioxidants such as BHT, THT, xantofylls, and tocopherol; and,
6) Surface modifiers such as surfactants, including, but not limited to: polyoxyalkylene block copolymers of the formula Y[(A)„-E-H]X where A is a polyoxyalkylene moiety, x is at least 2 , Y is derived from water or an organic compound containing x reactive hydrogen atoms; E is a polyoxyethylene moiety, n can be from 5 to 500; poloxamers; poloxamines; tyloxapol; tetronics; polyvinylpyrrolidone; polyvinyl alcohol; polyethylene glycol; amino acids and bioactive compounds that will bind with a specific receptor in the body such as immunoglobulins, lectins and ligands.
EXAMPLE 1 (Metal Ion - Lipid Microparticle Without Drug or Active Agent) This Example comprises a typical metal ion - lipid microparticle that is produced using this technology but the microparticle is without the drug or active agent. The microparticle of this Example is shown in Figure 1. Since the main component of the particle is the lipid, which tends to be more plastic in physical characteristics than most of the excipients normally used, the surface of the particle tends to be highly irregular.
The metal ion-lipid complex based microparticle composition of Example 1 was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a liposome suspension in which 1.1 g of Lipoid SPC-3 (hydrogenated phosphatidylcholines from soy) was dispersed in 25 g of deionized water ("Dl water"). Other organic solvents that can be used are DMSO, DMF, EtOH, MeOH, Et20 and Me20. The liposome suspension was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse suspension was
homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5. It is also possible to utilize non-hydrogenated and partially hydrogenated soy and egg phosphatidylcholine as the lipid in these Examples. Preparation B contained 0.143 g of CaCI2»2H20 and 0.21 g of lactose (the lactose was used to mimic a drug) dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 85°C, outlet temperature « 62°C, aspirator = 90%, pump = 2.2 mL/min, and nitrogen flow = 2400 L/h. In practicing the invention, inlet temperatures can vary within the range of approximately -10 to 200° C and outlet temperatures can vary within the range of approximately -20 to 150° C.
The mean volume aerodynamic particle size of the dry powder was approximately 2.48 μm, measured using an Amherst Aerosizer (Aerosampler module) by dispersing the resulting dry powder with an active dry powder inhaler. Visualization of particle size and morphology was achieved via electron microscopy. The microparticles were first treated with osmium tetraoxide vapor and then affixed on double sticky graphite tape to an aluminum stub. The sample was sputter-coated with a 250 A layer of gold/palladium, and imaged on a stereoscan 360 SEM (Cambridge, UK Microscope) operated at an accelerating voltage of 20 keV and a probe current of 250 pA. An example of the microparticle obtained by the method of Example 1 is shown in Figure 1. In general, the microparticles of this Example had a weight ratio of Phospholipid ("PL") to lactose to calcium chloride ("CaCI2*2H20 ") of about 75:15:10.
EXAMPLE 2 (Metal Ion - Lipid Microparticle Without Drug or Active Agent) Example 2 shows that in order to fully stabilize the microparticle of the present invention, all of the phospholipid has to be forming a complex with the metal ion.
The metal ion-lipid complex based microparticle composition of this Example was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a liposome suspension in which 1.07 g of distearoyl phosphatidylcholine ("DSPC") was dispersed in 25 g of Dl water. The liposome suspension was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min and then homogenized as in Example 1.
Preparation B contained 0.143 g of CaCI2*2H20 and 0.21 g of lactose (the lactose was used to mimic a drug) dissolved in 10 g of hot Dl water. While the preparations containing the lipid and metal are usually prepared separately, it is possible to combine the lipid and metal directly. The combined feed preparation (preparations A and B) was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 100°C, outlet temperature = 67°C, aspirator = 90%, pump = 2.2 mL/min, nitrogen flow = 2400 L/h. The mean volume aerodynamic particle size of the resulting dry powder was approximately 2.91 μm, this was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler. The mean geometric particle size of the powder as measured by the Sympatec particle size analyzer was approximately 2.76 μm. A MDI suspension was done with the powder (0.55%
w/w) in HFA 134a. The suspension had the appearance of loose 3D-flocculated material after standing for more than one minute. The particle size was analyzed using the Aerosampler (Amherst) and the mean volume aerodynamic diameter was approximately 3.48 μm.
In general, the microparticles of this Example had a PL: lactose: CaCI2»2H20 weight ratio of about 75:15:10. EXAMPLE 3 (Metal Ion - Lipid Microparticle With a Release Kinetic Modifier)
Example 3 shows the microparticle of the present invention in conjunction with the release kinetic modifier, polyvinyl pyrrolidone ("PVP"). The use of release kinetic modifiers such as PVP will slow down the release of incorporated drugs.
The metal ion-lipid complex based microparticle composition of Example 3 was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a liposome suspension in which 0.93 g of DSPC was dispersed in 25 g of Dl water. The liposome was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at
9000 rpm for about 5 min and then homogenized as in Example 1.
Preparation B contained 0.214 g of CaCI2»2H20 and 0.21 g of lactose (the lactose was used to mimic a drug) and 0.071 g of PVP 30K dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 100°C, outlet temperature = 67°C, aspirator = 90%, pump = 2.2 mL/min and nitrogen flow = 2400 L/h. The mean volume aerodynamic particle size of the dry powder was approximately 3.24 μm which was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler. The mean geometric particle size of the powder as measured by the Sympatec particle size analyzer was approximately 2.63 μm.
The microparticle of Example 3 had a PL: lactose: CaCI2«2H20: PVP weight ratio of about 65:15:15:5.
EXAMPLE 4 (Comparison of Various Formulations of Microparticles) In Example 4, three spray dried powders were formulated to compare the effect of formulation, composition and morphology. A) Sample 1 (Metal Ion Complex With Blowing Agent)
The metal ion-lipid complex based microparticle of this sample was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a fluorocarbon-in-water emulsion in which 29 g of perfluorooctyl bromide, a blowing agent, was dispersed in 27 g of Dl water with the aid of 1.32 g of dimyristoyl phosphatidylcholine ("DMPC") emulsifier. The emulsion was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The fluorocarbon was then added dropwise under mixing. The coarse emulsion was homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.164 g of CaCI2«2H20 and 0.164 g of lactose dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions:
inlet temperature - 75°C, outlet temperature = 55°C, aspirator - 90%, pump = 2.2 mL/min, nitrogen flow = 2500 L/h.
The microparticle of sample 1 had a weight ratio of PL: lactose: CaCI2«2H20 of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approximately 2.3 μm which was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler. B) Sample 2 (Lipid Microparticle and Blowing Agent Without Metal Ion)
The lipid based microparticle composition of this sample was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a fluorocarbon-in-water emulsion in which 29 g of perfluorooctyl bromide was dispersed in 27 g of Dl water with the aid of 1.32 g of DMPC emulsifier. The emulsion was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The fluorocarbon was then added dropwise under mixing. The coarse emulsion was homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.164 g of lactose dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature
= 75°C, outlet temperature = 55°C, aspirator = 90%, pump = 2.2 mL/min and nitrogen flow - 2500 L/h. The mean volume aerodynamic particle size of the dry powder was approximately 3.0 μm which was measured using an
Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
The microparticle of sample 2 had a weight ratio of PL: lactose: CaCI2 of about 90:10:0. C) Sample 3 (Metal Ion Lipid Microparticles Without Blowing Agent)
The metal ion-lipid complex based microparticle composition of this sample was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying.
Preparation A was comprised of a liposome suspension of 1.26 g of DMPC dispersed in 28 g of hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse liposomes were homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.164 g of CaCI2«2H20 and 0.164 g of lactose dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 75°C, outlet temperature = 55°C, aspirator = 90%, pump = 2.2 mL/min and nitrogen flow = 2500 L/h.
The microparticles of sample 3 had a weight ratio of PL: lactose: CaCI2»2H20 of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approximately 6.4 μm, which was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
Approximately 200mg of each of the samples were transferred to 10 mL empty vials and were labeled as samples 1, 2 and 3. Sample 1 and sample 2 had similar particle morphology (both have very low particle density due
to the use of blowing agents). Sample 2 (no calcium in formulation) did not present the formation of the metal ion-lipid complex. Sample 3 (i.e., metal ion-lipid complex formation) had the same formulation as sample 1 but no blowing agent was used. All vials were introduced into a vacuum oven set at 65°C and the samples were observed for any physical changes. At about 3 minutes, sample 2 started melting and within a few more minutes the entire sample had melted (fused into lumps). Samples 1 and 3 were heated for a total of 30 minutes and no observable physical changes were observed. Samples 1 and 2 had the same particle morphology but sample 2 did not present the formation of the metal ion-lipid complex. Sample 3 (i.e. metal ion-lipid complex formation) had the same formulation as sample 1, but no blowing agent was used. The three formulations demonstrate that stability is dictated by the formation of the metal ion-lipid complex formation and not by the morphology of the particle. Morphology will only affect the density and the aerodynamic size of the particles. Table I summarizes the effect of morphology and metal ion-lipid complexation, on particle size and stability.
i) Blowing agent used ii) Calcium-phospholipid complex
EXAMPLE 5 (Metal Ion -Lipid Formation Not Affected By Lipophilic Drug)
Example 5 shows how a lipophilic drug can be incorporated with the phospholipid, without affecting the formation of the metal ion - lipid complex. It also shows that in order to fully stabilize the particle, the lipid has to be forming a complex with the metal ion.
An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray- drying. Preparation A was comprised of a liposome preparation in which 0.57 g of Indomethacin (Sigma) was previously incorporated with 2.0 g of SPC-3 emulsifier (Hydrogenated soy phosphatidylcholine) by dissolving the Indomethacin and the SPC-3 in 5 mL of methanol followed by evaporation to dryness. This mixture was dispersed in 57 g of Dl water. The liposomes were prepared by first dispersing the phospholipid/drug in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The liposomes were further homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5. In practicing the present invention, the drug or active agent can also be added to the already formed microparticle by conventional means.
Preparation B was comprised of 0.286 g of CaCI2»2H20 in 5 g of hot Dl water. Preparation A and Preparation B were combined and the combined feed preparation was spray-dried with a standard B-191 Mini spray- drier under the following conditions: inlet temperature = 85°C, outlet temperature = 59°C, aspirator = 83%, pump = 2.2 mL/min, nitrogen flow = 2400 L/h. The resulting microparticle had a PL: Indomethacin: CaCI2*2H20
weight ratio of 70:20:10. The mean volume aerodynamic particle size of the dry powder was of 2.150 μm. This was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
The spray dried powder (50 mg) was then hand filled into aluminum canisters (Presspart Inc.) and dried in a vacuum oven at 40°C (25 mmHg) for 24 hours. The pMDI valves (DF 30/50 Valois) were crimped-sealed onto the canisters (another set was crimped on glass vials) and the canisters were filled with 10 g of HFA-134a (DuPont) by overpressure through the valve stem. Initial particle size was measured using an eight stage Andersen cascade impactor in conformance to USP protocol by measuring the drug concentration in each of the stages of the Andersen cascade impactor. Particle size analysis of the pMDI was of 3.84μm with a fine particle fraction of 61%. The fine particle fraction is defined as the percentage of drug which is deposited into respirable regions of the lung (i.e., stage
2 through filter [F]), divided by the total amount of drug leaving the device ( i.e., stages -1 thought F). The suspension was very stable even after settling for more than one minute, and resembling the aspect of milk.
One hundred mg of the dry powder was then transferred to a 5 mL glass vial and heated for 30 minutes at a temperature of 90°C. The sample was cooled down and 53 mg of sample transferred into an aluminum canister (Presspart Inc.) and dried in a vacuum oven at 40°C (25 mmHg) for 24 hr. The pMDI valves (DF 30/50 Valois) were crimped-sealed onto the canisters (another set was crimped on glass vials) and the canisters were filled with 10 g of HFA-134a (DuPont) by overpressure through the valve stem. Particle size analysis of the pMDI was of 4.30 m with a fine particle fraction of 49%.
A similar experiment to the above experiment was performed but the microparticle had a PL: Indomethacin: CaCI2 »2H20 weight ratio of 76:21:3. The particle size of the pMDI for this formulation was 3.93 μm with a fine particle fraction of 56%. When the sample was heated at 90°C for 30 minutes the entire sample melted within
3 minutes.
EXAMPLE 6 (Magnesium Chloride as the Metal) Example 6 shows that other metal ions can be used to stabilize the powders via the formation of the metal ion - lipid complex.
An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray- drying. Preparation A was comprised of a liposome preparation in which 0.54 g of Indomethacin (Sigma) was previously incorporated with 1.92 g of SPC-3 emulsifier (Hydrogenated soy phosphatidylcholine) by dissolving the Indomethacin and the SPC-3 in 5 mL of methanol followed by evaporation to dryness. This mixture was dispersed in 57 g of Dl water. The liposomes were prepared by first dispersing the phospholipid/drug in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The liposomes were further homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B was comprised of 0.395 g of MgCI2»6H20 in 5 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 85°C, outlet temperature = 59°C, aspirator = 83%, pump = 2.2 mL/min, nitrogen flow = 2400 L/h. The resulting
microparticle had a PL: Indomethacin: CaCI2»2H20 weight ratio of 70:20:10. The mean volume aerodynamic particle size of the dry powder was of 2.390 μm, this was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
The spray dried powder (50 mg) was hand filled into aluminum canisters (Presspart Inc.) and dried in a vacuum oven at 40°C (25 mmHg) for 24 hr. The pMDI valves (DF 30/50 Valois) were crimped-sealed onto the canisters (another set was crimped on glass vials) and the canisters were fill with 10 g of H FA- 134a (DuPont) by overpressure through the valve stem. The suspension was very stable even after settling for more than one minute, and resembling the aspect of milk. Initial particle size was measured using an eight stage Andersen cascade impactor, in conformance with USP protocol by measuring the drug concentration in each of the stages of the Andersen cascade impactor. Particle size analysis of the pMDI was of 3.93 m with a fine particle fraction of 56%. The fine particle fraction is defined as the percentage of drug which is deposited into respirable regions of the lung (i.e., stage 2 through filter [F]), divided by the total amount of drug leaving the device ( i.e., stages -1 thought F).
EXAMPLE 7 (Effect of the Metal Ion On Stability) Two dry pharmaceutical preparations of metal ion-lipid complex based microparticles were manufactured by a spray dry process in order to illustrate the differences in thermal stability of two compositions, sample 4 and sample 5. Sample 4 did not have the required amount of calcium to form the metal ion-lipid complex while sample 5 was formed of a metal ion-lipid complex. A) Samples 4 and 5
Both samples 4 and 5 were prepared as follows. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of 0.75 g of DSPC emulsifier in 25 g of Dl water. The preparation was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse liposome was homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.079 g of CaCI2»2H20 for sample #4 and 0.165 g of CaCI2«2H20 for sample #5 and 0.74 g of lactose dissolved in 10 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 100°C, outlet temperature = 70°C, aspirator = 90%, pump = 2.2 mL/min, nitrogen flow = 2500 L/h. The microparticles of sample 4 had a weight ratio of PL: lactose: CaCI2»2H20 of about 48:47:5. The microparticles of sample 5 had a weight ratio of PL: lactose: CaCI2»2H20 of about 45:45:10. Approximately 200 mg of each of the dry powders were transferred to 10 mL empty vials and were labeled as samples 4 and 5. Sample 4 had the lowest amount of calcium chloride while sample 5 had the highest. Both vials were introduced into a vacuum oven that was set at 100°C and the samples were observed for any physical changes. At about 20 minutes, sample 4 started melting and within a few more minutes the entire sample had melted (fused together into lumps). Sample 5 was heated for a total of 60 minutes and no observable physical change was observed. The mean volume aerodynamic particle size of the dry powder (sample 5) was approximately 2.2 μm
before and after heating. This was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
This Example shows the importance of fully stabilizing the lipid by the formation of the metal ion - lipid complex. Small amounts of calcium act as desiccants and will not modify the packaging of the phospholipid to reduce the harmful effects of water sorption. The amplification process (Ahlneck 1990, Int. J. Pharm., 62, 87 - 95) is a second reason to fully stabilize the lipid by the formation of the metal ion - lipid complex.
EXAMPLE 8 (Effect of Moisture on Stability Of Microparticles) This Example showed that if the samples exemplified in Example 7 are exposed to water and absorb water vapor, the plasticizing effect of water decreases its Tg approximately following the Gordon-Taylor equation:
r (wϊTgl )+(Kw2Tg2)
Smix w1 +Kw2 [6]
Referring to Fig. 2, the graph demonstrates the relationship between the storage temperature and water content and exemplifies what would be the effect of the decrease in Tg by the amount of water that has been absorbed. If 10% water is absorbed by both powders, sample 4 would decrease its Tg from 80°C to 20°C. Consequently, the resulting particle would be likely to be very unstable if the powder is stored at 40°C. I n contrast, sample 5 would decrease its
Tg from 120°C to about 50°C and would be much more stable even if stored at 40°C.
EXAMPLE 9 (Effect of a Counter Ion On Thermal Stability) In Example 9, two dry pharmaceutical preparations microparticles are manufactured by a spray dry process in order to illustrate the differences in thermal stability of both compositions (one having the negative effect of the counter-ions that will compete with the metal-lipid complex [sample 6], while the other sample [sample 7] does not).
A) Sample 6 (Metal Ion - Lipid Microparticle With Counter Ion That Impedes the Complex Formation)
An aqueous preparation was prepared by mixing three preparations (preparations A, B and C) immediately prior to spray drying. Preparation A was comprised a fluorocarbon-in-water emulsion in which 191 g of perfluorooctyl bromide was dispersed in 198 g of Dl water with the aid of 4.75 g of DSPC emulsifier. The emulsion was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The fluorocarbon was then added dropwise under mixing. The coarse emulsion was homogenized under high pressure
(18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.413 g of CaCI2«2H20 dissolved in 5 g of Dl water. Preparation C contained 5.17 g of albuterol sulfate USP ("Al") (bronchodilator) dissolved in 46 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 85°C, outlet temperature = 61 °C, aspirator = 82%, pump = 2.2 mL/min, nitrogen flow = 2500 L/h. The resulting
microparticle of sample 6 had a PL: Al: CaCI2*2H20 weight ratio of about 46: 50: 4. Sample 6 is the same formulation as described in Dellamary, 2000, 17 Pharm. Res., 2, 168 - 174.
This sample shows that calcium addition to a formulation will not always result in the formation of a metal ion - lipid complex. If the counter ion competes with the formation of the metal ion - lipid complex, the final product will not show an improvement in the Tm that is responsible for the stability of the powder against the harmful effects of water sorption. Calcium, in the form of calcium sulfate in the sample, is simply acting as a desiccant and does not modify the packaging of the phospholipid to reduce the harmful effects of water sorption. B) Sample 7 (Metal Ion - Lipid Microparticle Without Counter Ion)
An aqueous preparation is prepared by mixing preparations A and B immediately prior to spray drying. Preparation A comprises a liposome suspension in which 5.714 g of distearoylphosphatidylcholine (DSPC) is dispersed in 190 g of Dl. The liposome is prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse liposome suspension is homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contains 0.95 g of CaCI2*2H20, and 2.86 g of micronized albuterol free base dissolved/suspended in 16 g of hot Dl water. The combined feed preparation is spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 85°C, outlet temperature = 61 °C, aspirator = 85%, pump = 2.2 mL/min, nitrogen flow = 2400 L/h. The resulting microparticle of sample 7 has a PL: Albuterol: CaCI2»2H20 weight ratio of about 60: 30:10.
Both samples are dried in an oven at 60°C for one hour prior to any experiment. Approximately 200 mg of each of the dry powders are transferred to 10 mL empty vials and were labeled as samples 6 and 7. Sample 6 had the albuterol sulfate that competes with the effective binding of the calcium to the phospholipid while sample 7 has no compound to compete with the calcium-phospholipid complex. Sample 6 was introduced into a vacuum oven that was set at 100°C and the sample was observed for any physical changes. At about 25 minutes, sample 6 started melting and within a few more minutes, the entire sample had melted. Sample 7 is expected to have a transition temperature above 100°C, since there is not counter ions that will impede the formation of the metal-ion lipid complex. A differential scanning calorimeter assay (Mettler Toledo Star) was performed on samples 6 showing a transition temperature at 58°C (corresponding to the gel-liquid crystalline transition of DSPC).
The spray dried powder of sample 6 was then hand filled into aluminum canisters (Presspart Inc.) and dried in a vacuum oven at 40°C (25 mmHg) for 3-4 hr. The pMDI valves (BK RB700 Bespak Inc.) was crimped-sealed onto the canisters and a Pamasol (Pfaffikon) model 2005 was used to fill the canisters with HFA-134a (DuPont) by overpressure through the valve stem. Initial particle size was measured using an eight stage Andersen cascade impactor, in conformance to USP protocol by measuring the drug concentration in each of the stages of the Andersen cascade impactor. The cans were stored in an incubator and held at 40°C and 75% RH in accordance to the USP for accelerated stability. Samples were taken at time points of 1, 3 and 6 months. Particle size was measured using the Andersen cascade impactor. Mass median aerodynamic diameters (MMAD) and geometric standard deviations (GSD)
were evaluated by fitting the experimental cumulative function to a log-normal distribution with two-parameter fitting routine (Scientist, MicroMath):
, f\nDaer -lnMMADλ l + erf —
Mass = X lnGSD J -
2
[7]
where the dependent variable is the mass of drug deposited on a given stage and the independent variable, Daer, is the aerodynamic diameter value for a given stage according to manufacture.
Figure 3 shows the effects of high stress conditions (40° C/75% RH) on pMDIs where sample 6 has the negative effects of the counter-ions that will compete with the metal-lipid complex. Sample 6 had a Tm of about 58°. Increasing the Tm to about 90°C or above by the promoting the formation of the metal ion-phospholipid complex, it will be possible to prevent the loss in formulation performance after storage that is seen with formulation 6. Figure 4 shows the theoretical relationship between the critical water content (%) calculated from Figure 4 at which Tm is lowered to the storage temperature as a function of "dry" Tm at a storage temperature of 40°C for the two different formulations. The albuterol sulfate formulation that impedes the formation of the calcium-phospholipid complex can only absorb up to 3% water before the structure collapses at a temperature of 40°C, while the albuterol free base formulation that does not impede the calcium-phospholipid complex can withstand (theoretically based on the Gordon - Taylor equation) up to 11 % by weight water at 40 °C.
It is contemplated that using larger amounts of highly soluble metal ions will overcome the negative effect of the counter ion. By manufacturing the preparation with albuterol free base [Sample 7) instead of the albuterol sulfate (sample 6), it is expected that the negative action of the counterions on the formation of the calcium lipid complex can be eliminated.
EXAMPLE 10 (Metal Ion - Lipid Microparticle With Budesonide With and Without Blowing Agent) Example 10 shows the suspension stability and dispersability of budesonide formulated in calcium- phospholipid complex with and without blowing agent. A) Sample 8 (Metal Ion - Lipid Microparticle With Blowing Agent) An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a fluorocarbon-in-water emulsion in which 26 g of perfluorooctyl bromide was dispersed in 33 g of Dl water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The emulsion was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The fluorocarbon was then added dropwise under mixing. The coarse emulsion was homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.162 g of CaCI2*2H20 and 0.162 g of budesonide dissolved/suspended in 4 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the
following conditions: inlet temperature = 85°C, outlet temperature = 62°C, aspirator = 100%, pump = 2.2 mL/min, nitrogen flow = 2400 L/h. The resulting microparticle of sample 8 had a PL: budesonide: CaCI2*2H20 weight ratio of about 80: 10: 10. The mean volume aerodynamic particle size of the dry powder was approximately 4.1 μ , this was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler.
B) Sample 9 (Metal Ion - Lipid Microparticle Without Blowing Agent)
An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a liposome suspension in which 1.90 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine) was dispersed in 47 g of Dl water. The liposomes were prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse liposomes were homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.238 g of CaCI2«2H20 and 0.238 g of budesonide dissolved/suspended in 4 g of hot Dl water. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature = 85°C, outlet temperature = 62°C, aspirator - 100%, pump = 2.2 mL/min, nitrogen flow = 2400 l/hr. The mean volume aerodynamic particle size of the dry powder was approximately 4.2 μm, this was measured using an Amherst Aerosizer (Aerosampler module) by dispersing the dry powder with an active dry powder inhaler. The resulting microparticle of sample 9 had a PL: budesonide: CaCI2»2H20 weight ratio of about 80:10:10.
The spray dried powders (50 mg) were then hand filled into aluminum canisters (Presspart Inc.) and dried in a vacuum oven at 40°C (25 mmHg) for 24 hr. The pMDI valves (DF 30/50 Valois) were crimped-sealed onto the canisters (another set was crimped on glass vials) and the canisters were filled with approximately 10 mg of HFA- 134a (DuPont) by overpressure through the valve stem. Initial particle size was measured using an eight stage Andersen cascade impactor, in conformance to USP protocol, by measuring the drug concentration in each of the stages of the Andersen cascade impactor. The fine particle fraction is defined as the percentage of drug which is deposited into respirable regions of the lung (i.e., stage 2 through filter (F)), divided by the total amount of drug leaving the device { i.e., stages -1
lOO∑m,
FPF = -1A^ —
through F). Table II summarizes the particle sizing of budesonide formulated in the metal ion-phospholipid complex in pMDIs using HFA 134a.
1- Volume mean aerodynamic diameter (Amherst Aerosizer)
2- Mean mass aerodynamic diameter (Andersen Cascade)
3- Geometric standard deviation (Andersen Cascade)
4- Fine particle fraction (Andersen Cascade)
Scanning Electron Microscopy Images of sample 8 (with blowing agent) are shown in Figures 5A and 5B. Note the high surface area and the cavities on the particles surface. The cavities are approximately half spheres.
The powders were then tested in a dry powder inhaler ( FlowCaps, Hovione Lisbon, Portugal). A modification of the USP protocol was employed to minimize particle bouncing and entrainment. Plates 2 through 7 were inverted, loaded with a Gelman # 60010 A/E glass fiber filter and 4 mL Dl water was dispensed onto them. The powders were actuated from the Hovione FlowCaps DPI device for 5 seconds into a 28.3 L/min vacuum source. The Andersen impactor was then disassembled and extracted with 100% methanol. The extract was centrifuged at 14,000 rpm for 30 minutes in order to separate any glass fiber that could interfere with the assay. Budesonide quantitation was performed by UV spectrophotometry at a wavelength of 242 nm against a blank. Table II Summarizes the particle sizing of budesonide formulated in the metal ion-phospholipid complex using a passive dry powder inhaler (FlowCaps, Hovione).
1- Mean mass aerodynamic diameter (Andersen Cascade)
2- Geometric standard deviation (Andersen Cascade)
3- Fine particle fraction (Andersen Cascade)
Scanning Electron Microscopy Images of sample 9 (no blowing agent) are shown in Figures 6A and 6B. Note the surface area and the absence of large cavities on sample 9 in Figures 6A and 6B in comparison to sample 8 which is shown on Figures 5A and 5B. The only difference between samples 8 and 9 is that sample 8 was manufactured with a blowing agent to reduce particle density. Bulk density measurements of sample 8 and sample 9 were 0.03 and 0.1 g/mL respectively. Both samples 8 and 9 showed good performance when evaluated as pMDIs and dry powder inhalers. The main difference observed between both particles was their bulk density, which can be attributed to the extensive cavitation seen on sample 8 (Figures 5A and 5B). The surface of the microparticles in sample 9 as shown in Figures 6A and 6B is wrinkled without a large number of open pores due to the plastic nature of the metal ion - lipid complex. Both
suspensions in propellant HFA 134a resembled a milky appearance even after the samples were settled for more than one minute.
EXAMPLE 11 (Metal Ion - Lipid Microparticle With Hemocγanin) Example 11 shows the feasibility of producing metal ion-lipid complex microparticles containing large proteins, while maintaining the activity of the protein.
The metal ion-lipid complex based microparticle composition of this Example were manufactured by a spray dry process. An aqueous preparation was prepared by mixing three preparations A, B and C immediately prior to spray drying. Preparation A was comprised of 0.75 g of Lipoid EPC3 (hydrogenated egg-phosphatidylcholine) emulsifier in 40 g of Dl water. The liposome was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. The coarse liposome was homogenized under high pressure (18,000 psi) for 5 discrete passes with an Avestin Emulsiflex C5.
Preparation B contained 0.107 g of CaCI2»2H20 and 0.107 g of lactose dissolved in 10 g of hot Dl water. Preparation C contained 10 mg of hemocyanin, keyhole limpet from megathura crenulata (MW 3x10B-7.5x106), that was dissolved in 2 mL of Dulbecco's PBS buffer. Preparations A and B were combined and an aliquot (6.5 g) of this preparation was mixed with the protein preparation C. The combined feed preparation was spray dried with a standard B-191 Mini spray drier under the following conditions: inlet temperature - 85°C, outlet temperature = 62°C, aspirator = 90%, pump - 2.2 mL/min, nitrogen flow = 2500 L/h. The resulting microparticle had a PL: Hemocyanin: CaCI2»2H20 weight ratio of about 80:10:10. Activity of the protein was confirmed by an ELISPOT bioassay technique, where the T cells ability to produce cytokines was measured in the presence and in the absence of microparticles. The results were compared to freshly prepared hemocyanin, the activity of the hemocyanin incorporated in the microparticles was of the same magnitude as the standard hemocyanin preparation.
EXAMPLE 12 (Metal Ion - Lipid Microparticle With Insulin) Example 12 shows the incorporation of insulin with the phospholipid-metal ion of the present invention for treatment of diabetes and where the phospholipid-metal ion serves as a penetrater enhancer for the pulmonary delivery of insulin. Since the insulin is already incorporated into a lung surfactant type of media, the insulin absorption into the lung tissue should be enhanced by this situation.
The stable dry pharmaceutical preparation metal ion - lipid based microparticle of this Example was manufactured by a spray dry process. An aqueous preparation was prepared by mixing two preparations, A and B, immediately prior to spray drying. Preparation A was comprised of a liposome dispersion in which 1.71 g of hydrogenated soy phosphatidylcholine was dispersed in 50 g of Dl water. The liposome dispersion was prepared by first dispersing the phospholipid in hot Dl water with a T-25 Ultraturrax at 9000 rpm for about 5 min. Preparation B contained 0.286 g of CaCI2»2H20 and 0.86 g of insulin zinc salt (Sigma) in 10 g of Dl water. The insulin zinc salt was dissolved by acidifying with 1 M HCI. The combined feed solution was spray dried with a standard B-191 mini spray drier under the following conditions: inlet temperature = 85°C; outlet temperature= 63°C; aspirator = 85%; pump
= 2.2 mL/min; nitrogen flow = 2400 L/hr. The resulting microparticle had a PL: CaCI2»2H20: Insulin weight ratio of 60:10:30.
EXAMPLE 13 (Single Preparation Feedstock) The particles of Example 10, sample 9 are prepared by dispensing the phospholipid (SPC-3) in a single aqueous preparation containing all of the solutes (CaCI2»2H20) and budesonide) in the combined 51 g of hot Dl water and homogenizing and spray drying as in Example 10, sample 9. Particles similar to sample 9 of Example 10 were obtained.
EXAMPLE 14 (Increased Density and Refractive Index [Polarizability] Particles)
The method of Example 10, sample 9 is employed to produce particles with four times higher CaCI2*H20 concentration, with a PL: budesonide: CaCI2*2H20 weight ratio of about 61:30:9 by substituting 0.952 g of
CaCI2*H20 for the 0.238 g of budesonide employed in the previous experiment. The excess calcium chloride, in addition to forming metal ion - lipid complexes, increases the density of the final particles to more closely match that of MDI propellents and reduces the creaming rate to yield more accurate dosing. It is expected that a similar effect would be obtained by adding 0.714 g of sodium chloride to the formula of sample 9 in Example 10. These formulas would be most advantageous where consistent MDI dosing is most important.
EXAMPLE 15 (Slow Dissolving Particle Employing the Formation of Calcium Carbonate)
The particles of Example 11 are prepared as in Example 11 with the exception that four times the CaCI2»H20 is employed and thus 0.428 g of CaCI2«H20 is substituted for the 0.107 g of CaCI2«H20 utilized in Example 11. The particles thus formed are then exposed to carbon dioxide either in the spray dryer gas stream while forming the particles or in a gas/vacuum chamber after the particles are formed. Slowly dissolving calcium carbonate is formed on the surfaces of the particles by the reaction of carbon dioxide with excess calcium ion present in the particles. This calcium carbonate slows the dissolution of the particles and the release of hemocyanin from the particles in vivo. An alternative method of forming calcium carbonate on the particles would be to express them to the vapors of a volatile carbonate such as ammonium carbonate during spray drying or in a vacuum chamber. This would have the advantage of not greatly shifting the pH of the particles as the ammonium carbonate would react with calcium chloride to make calcium carbonate and volatile ammonium chloride.
EXAMPLE 6 (Slow dissolving Fatty Acid Salt Particles)
The excess calcium chloride formula of Example 8 can be further modified by the addition of sodium stearate to the phospholipid, by substituting 10% of the weight of phospholipid with an equal weight of sodium stearate before dispersing and homogenization. Upon spray drying, some of the excess calcium ion will form water insoluble calcium stearate within the particle which will slow its dissolution and release the active agent contained within the particle.
Other fatty acids or fatty acid salts that form water insoluble calcium salts are also contemplated.
EXAMPLE 17 (Avoiding Precipitation and Competing Ion Effects) It is contemplated that acceptable particles can be formed from the formula of Example 9, sample 6 if the calcium chloride content of the particles in moles is raised to more than the total number of moles of phospholipid plus
twice the number of moles of albuterol sulfate and a modified spray drier atomizer nozzle is employed to mix the calcium ion containing solution B with a premixed preparation comprised of the combined mixtures of solutions A and C (phospholipid, albuterol sulfate containing solutions) immediately before ato ization in the spray drier. The stable particles thus formed contain an excess of calcium ion to overcome the competing effects of the sulfate ion and thus still form the metal ion - lipid complexes described above. Mixing the sulfate containing solution with the calcium ion containing solution immediately before spray drying, this avoids the negative effects of calcium sulfate precipitation on the atomization process and thus the particle size distribution.
EXAMPLE 18 (Treatment of Diabetes With Insulin Containing Metal Ion -Lipid Microparticle) Example 18 shows how the present invention can be used to treat Type I or Type II diabetes in human or animal subjects.
In this Example, treatment of patients suffering from Type I or Type II diabetes is demonstrated using the insulin containing microparticle of Example 12. After formation, the insulin containing microparticle composition of Example 12 is introduced into a holding chamber of a DPI, pMDI, nebulizer, insufflator or liquid dose inhaler and is aerosolized by any conventional means. The insulin containing microparticle is then introduced into the lungs of a subject by the patient inhaling on the mouthpiece of the DPI or pMDI by taking long, deep breaths to draw the aerosolized dispersion into the lungs.
This method of introducing aerosolized insulin containing microparticles into the lungs of a patient to treat diabetes has many advantages over subcutaneous injections of insulin such as ease of use, rapid insulin absorption and rapid glucose response. The efficiency of systematic insulin delivery by this method is thought to be in the range of about 40% - 60%. Individual dosages of insulin, per inhalation, depend on the weight ratio of insulin in the particular microparticle, but is generally within the range of 0.25 mg to 5 mg per inhalation. Generally, the total dosage of insulin desired during a single respiratory administration will be in the range from about 0.5 mg to about 20mg of insulin.
Dosages of insulin, which are always expressed in USP units, must be based on the results of blood and urine glucose determinations and must be carefully individualized to attain optimum therapeutic effect. General guidelines on the dosage of insulin containing microparticles of the present invention administered intrapulmonary for treatment of juvenile diabetes in pediatric patients per single respiratory administration is approximately 1 - 1.5:1 by weight of insulin administered by the metal ion lipid particle of the present invention to the weight of insulin introduced by subcutaneous injections. For adult patients, the ratio is approximately 2:1. EXAMPLE 19 (Administration of Human Growth Hormone)
Example 19 shows how the present invention can be used to administer human growth hormone in human and animal subjects.
In this Example, administration of sermorelin acetate (which is the acetate salt of an amidated synthetic 29 amino acid peptide, GRF 1 - 29 -NH2) is demonstrated for treatment of idiopathic growth hormone deficiency in children with growth failure. A metal ion - lipid microparticle is formed according to the teachings of Example 12
(without the step of acidifying with HCI) by substituting sermorelin acetate for insulin. The sermorelin acetate containing microparticle composition is then introduced into a holding chamber of a DPI, pMDI, nebulizer, insufflator or liquid dose inhaler and is aerosolized by any conventional means. The sermorelin acetate containing microparticle is then introduced into the lungs of a subject by the patient inhaling on the mouthpiece of the DPI or pMDI by taking long, deep breaths to draw the aerosolized dispersion into the lungs.
Dosages of sermorelin acetate containing microparticle is generally in the range of .02 - .04 mg/kg of body weight once a day before bedtime. Treatment should be discontinued when the epiphyses are fused. Height should be monitored monthly and care should be taken to ensure that the child grows at a rate consistent with the child's age. Patients who fail to respond should be evaluated to determine cause of unresponsiveness. EXAMPLE 20 (Administration of Tobramycin)
Example 20 shows how the metal ion - lipid based microparticles of the present invention can be used for the administration of various antibiotics.
When a patient on mechanical ventilation has developed a nosocomial pneumonia and high pulmonary concentrations of antibiotics without systemic levels are desired, pulmonary delivery of antibiotics through a DPI , pMDI, insufflator, liquid dose inhaler or nebulizer may be desirable. Pulmonary delivery of antibiotics could also be useful when usage of broad spectrum antibiotics present toxicity problems. Antibiotics such as aminoglycosides (e.g., tobramycin), ansamycins (e.g., rifamycin), penicillins, chloramphenicol group antibiotics, peptides (e.g., vancomycin), linosamides (e.g., lyncomycin), macrolides (e.g., erythromycin) and tetracyclines (e.g., tetracycline) may be combined with the metal ion -lipid microparticle of the present invention for pulmonary administration. It is believed that formulations can be made that permit or disallow systemic absorption, depending on the clinical need.
In this Example, administration of tobramycin is demonstrated for the treatment of bacterial pneumonia. A metal ion - lipid microparticle is formed according to the teachings of Example 7, sample 5 where commercially available tobramycin free base is substituted for lactose. The resulting tobramycin metal ion - phospholipid complex is introduced into a holding chamber of a DPI , pMDI, nebulizer, insufflator or liquid dose inhaler and is aerosolized by any conventional means. The tobramycin metal ion phospholipid complex is then introduced into the lungs of a subject by the patient inhaling on the mouthpiece of the DPI or pMDI by taking long, deep breaths to draw the aerosolized dispersion into the lungs.
Depending on the stage and seriousness of pneumonia and assuming normal renal function, dosages in adults can range from .5 - 1 mg/kg of tobramycin per administration every eight hours not to exceed 2.5 mg/kg/day. EXAMPLE 21 (Administration of Ethambutol)
Example 21 shows the metal ion - lipid based microparticles of the present invention used with ethambutol as a tuberculostatic agent.
In a patient with pulmonary tuberculosis, it may be desirable to introduce a tuberculostatic agent directly into the site of infection. Systemic administration of ethambutol can be detrimental resulting in depigmentation of the tapetum lucidum of the eye and clinical visual loss. The administration of the drug directly to the pulmonary focus of
infection would be expected to reduce the amount of drug systemically administered. In this Example, administration of ethambutol is demonstrated for treatment of pulmonary tuberculosis. A metal ion - lipid microparticle is formed according to the teachings of Example 7, sample 5 where commercially available ethambutol hydrochloride is substituted for lactose. The resulting ethambutol metal ion - phospholipid complex is introduced into the holding chamber of a DPI, pMDI, nebulizer, insufflator or liquid dose inhaler and is aerosolized by any conventional means. The ethambutol metal ion - phospholipid complex is then introduced into the lungs of a subject by the patient inhaling on the mouthpiece of the DPI or pMDI by taking long, deep breaths to draw the aerosolized dispersion into the lungs.
Depending on the stage of tuberculosis, dosages for adults can range from 15 mg/kg per 24 hour period of ethambutol hydrochloride for patients who have not received previous antitubercular therapy and 25mg/kg per 24 hour period of ethambutol hydrochloride for adult patients who have had previous tuberculosis therapy. Administration should only be once a day. Ethambutol hydrochloride should not be used in children under thirteen years of age.
EXAMPLE 22 (Administration of Ibuprofen) This Example shows the metal ion - lipid based microparticles of the present invention used with ibuprofen. Due to the rapid bioavailability of intrapulmonary delivered drugs, it may be desirable to deliver an analgesic directly into the lungs. It may also be desirable to deliver an analgesic directly into the lungs to avoid Gl complications which sometimes occur due to oral delivery of analgesics. In this Example, ibuprofen, a nonsteroidal anti-inflammatory and analgesic agent, is combined with the microparticle of the present invention according to the teachings of Example 7, sample 5. In combining ibuprofen with the metal ion - lipid microparticle of the present invention, commercially available ibuprofen may be used. The resulting ibuprofen metal ion phospholipid complex is introduced into a holding chamber of the DPI, pMDI, liquid dose inhaler, nebulizer or insufflator and is aerosolized by any conventional means. The ibuprofen containing microparticle composition is then introduced into the lungs of a subject by the patient inhaling on the mouthpiece of the DPI or pMDI by taking long, deep breaths to draw the aerosolized dispersion into the lungs. Adult dosages can range from 100 - 150 mg of ibuprofen per inhalation for an adult subject, not to exceed
400 - 600 mg in a single respiratory administration for inflammatory conditions such as rheumatoid and osteoarthritis. Total dosage should not exceed 3 g daily. Dosages for juvenile arthritis should not exceed 400 mg daily for children weighing less than 20 kg, 600 mg for children weighing less than 20 - 30 kg and 800 mg daily for children weighing 30 - 40 kg. For relief of mild to moderate pain, the usual adult dosage is about 200 mg every 4 - 6 hours and may be increased if pain persists. For antipyresis in children from 6 months to 12 years of age, dosage should not exceed 7.5 mg/kg.
Other analgesics such as acetaminophen and aspirin may also be combined with the metal ion - lipid microparticle of the present invention according to the teachings of Example 7 and Example 22.
Claims (45)
- We claim:I. A microparticle for drug delivery wherein the microparticle is comprised of a metal ion-lipid complex.
- 2. The microparticle of claim 1 wherein the microparticle has a transition temperature of at least20° C above its recommended storage temperature for drug delivery.
- 3. The microparticle of claim 1 wherein the microparticle has a phospholipid concentration from about25-98% w/w, a drug or active ingredient concentration from about 0-80 % w/w and a metal-ion salt to lipid molar ratio greater than 0-2.
- 4. The microparticle of claim 1 wherein the presence of the metal ion raises the Tg of the microparticle at least 2 °C above that of the same microparticle without the metal ion.
- 5. The microparticle of claim 1 wherein the metal ion-lipid complex has a density measured by He displacement within the range of about 0.5-2.0 g/cm3.
- 6. The microparticle of claim 1 wherein the lipid component is comprised of a mixture of at least two lipids.
- 7. The microparticle of claim 1 wherein at least one lipid is a phospholipid.
- 8. The microparticle of claim 7 wherein the phospholipid is chosen from the group consisting of DPPC, DSPC, DMPC, dioctylphosphatidycholine, soy phosphatidylcholine, egg phosphatidylcholine and partially hydrogenated phosphatides and polymerizable phospholipids.
- 9. The microparticle of claim 1 wherein the metal ions are chosen from the group consisting of lanthanide metals, actinide metals, group lla and lllb metals, transition metals or mixtures thereof.
- 10. The microparticle of claim 1 wherein the metal ion is chosen from the group consisting of calcium, zinc, aluminum, iron and magnesium in the form of water soluble salts and mixtures thereof.
- I I. The microparticle of claim 1 further including one or more drugs or active agents.
- 12. The microparticle of claim 11 wherein the drug or active agents are chosen from the group consisting of antiallergics, antifungals, antimigraine, antianemics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, leukotriene inhibitors or antagonists, antihistamines, antiinflammatories, antineoplastics, anticholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, lectins, steroids, genetic material, viral vectors, antisense agents, monoclonal antibodies, proteins, peptides, therapeutically useful metal ions and gases and combinations thereof.
- 13. A powder composition comprising a plurality of microparticles for drug or active agent delivery wherein the microparticles are comprised of a metal ion-lipid complex.
- 14. The powder microparticle composition of claim 13 wherein a drug or active agent is incorporated with the metal ion-lipid complex.
- 15. The powder microparticle composition of claim 14 further including a compound selected from the group consisting of: disintegrants; insoluable, inorganic or organic matter, like calcium carbonate or polyesters; polysaccharides; polyvinylpyrrolidone; polyvinyl alcohol; polyethylene glycol; poloxamers; tyloxapol; poloxamines; methoxypropyleπe glycols; polyglycol copolymers; tetronics; cellulose esters; chitosan and derivatives; cellulose ethers; carboxymethylcellulose; hydroxymethylcellulose; carbopol; polyacrylic acids and salts; crosslinked polyacrylic acids; polylactides; polyglycolides; starches and derivatives or starches and other polysaccharides; methylated starches; ethylated starches; crosslinked starches; inulin; dextrans; dextran sulfates; cyclodextrins; polyoxyalkylene block copolymers of the formula Y[(A)n-E-H]x, where A is a polyoxyalkylene moiety, x is at least 2, Y is derived from water or an organic compound containing x reactive hydrogen atoms, E is a polyoxyethylene moiety, n can be from 5 to 500; peptides; polylysine; polyarginine; polyalanine; polyglycine and proteins albumins of bovine, milk, human, and egg; fatty acid metal salts; plasticizers; wetting agents; vitrifiers; antioxidants; BHT; THT; xantofylls; tocopherol; and mixtures thereof.
- 16. The powder microparticle composition of claim 13 wherein the lipid is comprised of at least one phospholipid.
- 17. The powder microparticle composition of claim 16 wherein the at least one phospholipid is selected from the group consisting of DSPC, DPPC, DMPC, dioctylphosphatidylcholine, soy phosphatidylcholine, egg phosphatidylcholine and partially hydrogenated phosphatides or mixtures thereof.
- 18. The microparticle composition of claim 14 wherein the microparticle has a mean volume aerodynamic particle size of about 0.5 μm to 7 m.
- 19. The powder microparticle composition of claim 13 wherein the drug or active agent is selected from the group consisting of albuterol, albuterol chloride, budesonide, fluticasone propionate, salmeterol xinafoate, formoterol fu arate, nicotine chloride, nicotine nitrate, tria cinolone acetonide, dexamethasone, beclomethasone dipropionate , gentamicin, gentamicin chloride, gentamicin sulfate, ciprofloxacin hydrochloride, taxol, amphotericin, amikacin, amikacin chloride, tobramycin, tobramycin chloride and tobramycin nitrate or mixtures thereof.
- 20. The powder microparticle composition of claim 13 wherein the drug or active agent is selected from the group consisting of insulin, albumin, enzymes, pulmozyme and immunoglobulins, genes, DNAzymes, ribozymes, oligodinucleotides, and monoclonal antibodies.
- 21. The powder microparticle composition of claim 13 wherein the microparticles are substantially non-hollow and non-porous.
- 22. The microparticle composition of claim 13 further comprising a powder modifying agent.
- 23. The powder microparticle composition of claim 22 wherein the powder modifying agent is a carbohydrate.
- 24. The powder microparticle composition of claim 23 wherein the carbohydrate is selected from the group consisting of lactose, sucrose, hydroxy ethyl starch; hetastarch, trehalose, mannose and mannitol.
- 25. A method of administering a drug or therapeutic or biologically active agent into a subject comprising administering to the subject a plurality of metal-ion lipid based microparticles further comprising a drug or active agent.
- 26. The method of claim 25 wherein the method of administration is selected from the group consisting of nebulization, insufflation, dry powder inhalation and aerosol inhalation.
- 27. The method of claim 25 wherein the microparticles may be administered by any of the following types of delivery: topical; respiratory; pulmonary; otic; anal; optic; vaginal; intramuscular; intravenous; intratracheal; intracuticular; intraperitoneal; nasal; pharyngeal; sinal; subcutaneous; intradural; extradural; intracisternal; and intrapleural delivery.
- 28. A stable microparticle composition for drug delivery wherein the microparticle is comprised of a metal ion-lipid complex formed by the following process: dispersing a phospholipid in water to create a first preparation; suspending a metal compound or salt in water to create a second preparation; adding a drug or active agent; combining the first and second preparations; and, spray drying the combined preparations to create a stable metal ion - lipid microparticle composition.
- 29. The microparticle composition of claim 28 wherein the phospholipid is selected from the group consisting of soy phosphatidylcholine, egg phosphatidylcholine, DPPC, DSPC, DMPC, dioctylphosphatidylcholine, and partially and fully hydrogenated phosphatides.
- 30. The microparticle composition of claim 28 wherein the metal ion is added in the form of calcium salt.
- 31. The microparticle composition of claim 28 wherein the combined preparation is spray dried with an inlet temperature within the range of -10 to 200°C and an outlet temperature within the range of -20 to 150°C.
- 32. The microparticle composition of claim of claim 28 wherein the combined preparation is spray dried with an inlet temperature within the range of 40 - 100 ° C and an outlet temperature within the range of 30 - 85 ° C.
- 33. The microparticle composition of claim 28 wherein the drug or active agent is added to one of the preparations selected from the group consisting of the first preparation, the second preparation and the combination of the first and second preparation.
- 34. The microparticle composition of claim 28 wherein the drug or active agent is added to the formed metal ion - lipid complex.
- 35. The microparticle composition of claim 28 wherein the drug or active agent is selected from the group consisting of albuterol, albuterol chloride, budesonide, fluticasone propionate, salmeterol xinafoate, formoterol fumarate, nicotine chloride, nicotine nitrate, triamcinolone acetonide, dexamethasone, beclomethasone dipropionate. gentamicin, gentamicin chloride, gentamicin sulfate, ciprofloxacin hydrochloride, taxol, amphotericin, amikacin, amikacin chloride, tobramycin, tobramycin chloride and tobramycin nitrate.
- 36. A method of forming a stable metal ion - lipid microparticle composition for drug delivery comprising the following steps: dispersing a phospholipid and suspending a metal in water; adding a drug or active agent; spray drying the preparation to create a stable metal ion - lipid microparticle composition.
- 37. The composition of claim 13 further comprising fatty acid or fatty acid salt to slow the release of the drug or active agent.
- 38. A method of treating diabetes by administering a composition comprising a powdered microparticle composition to a subject wherein the microparticles are comprised of a metal ion-lipid combination and further including the drug insulin.
- 39. The method of claim 38 wherein the microparticle composition is administered by a metered dose inhaler or dry powder inhaler.
- 40. The method of claim 38 wherein the composition is delivered to the subject by pulmonary delivery.
- 41. A stable microparticle composition for drug delivery wherein the microparticle is comprised of a metal ion- lipid complex formed by the following process: spray drying a preparation comprised of a dispersed metal ion - lipid complex and a drug or active agent.
- 42. The composition of claim 13 further comprising calcium carbonate within the particles formed during or after the formation of the particles.
- 43. The microparticle of claim 1 wherein the metal ion has more than a one positive charge.
- 44. A method of treating a patient comprising administering a therapeutic amount of drug - loaded metal ion - lipid microparticles.
- 45. A stable microparticle composition obtained by spray drying a combination of phospholipid, at least one metal compound and at least one drug or active agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/568,818 US7871598B1 (en) | 2000-05-10 | 2000-05-10 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US09568818 | 2000-05-10 | ||
PCT/US2001/014824 WO2001085137A2 (en) | 2000-05-10 | 2001-05-08 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001259637A1 true AU2001259637A1 (en) | 2001-11-20 |
Family
ID=24272868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001259637A Abandoned AU2001259637A1 (en) | 2000-05-10 | 2001-05-08 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
Country Status (9)
Country | Link |
---|---|
US (5) | US7871598B1 (en) |
EP (2) | EP2851067A1 (en) |
JP (2) | JP2003533449A (en) |
KR (2) | KR100845445B1 (en) |
AU (1) | AU2001259637A1 (en) |
CA (1) | CA2408464C (en) |
LU (1) | LU92678I2 (en) |
MX (1) | MXPA02011003A (en) |
WO (1) | WO2001085137A2 (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US20020106368A1 (en) * | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same |
US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
DK2283817T3 (en) | 2000-11-30 | 2016-09-05 | Vectura Ltd | Process for preparing particles for use in a pharmaceutical composition |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
EP1390012A4 (en) * | 2001-04-26 | 2009-10-28 | Novartis Ag | Novel methods and compositions for delivering macromolecules to or via the respiratory tract |
ATE508735T1 (en) * | 2001-12-19 | 2011-05-15 | Novartis Ag | PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES |
US8777011B2 (en) | 2001-12-21 | 2014-07-15 | Novartis Ag | Capsule package with moisture barrier |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
RU2389477C2 (en) | 2004-06-18 | 2010-05-20 | Новартис Ваксинз Энд Дайагностикс Инк. | Methods of treating endobronchial diseases |
JP2008503586A (en) | 2004-06-21 | 2008-02-07 | ネクター セラピューティクス | Compositions, methods and systems comprising amphotericin B |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
ITMI20051999A1 (en) | 2005-10-21 | 2007-04-22 | Eratech S R L | INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY |
CA2652797A1 (en) * | 2006-05-18 | 2007-11-29 | Tika Laekemedel Ab | Methods for the delivery of a .beta.2 agonist to induce bronchodilation and formulations for use in the same |
JP2010508069A (en) | 2006-10-25 | 2010-03-18 | ノバルティス アーゲー | Powder disperser, method of manufacturing and using the device, component used in the device and other devices |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
JP5207359B2 (en) * | 2008-03-28 | 2013-06-12 | 独立行政法人産業技術総合研究所 | Mass production method of metal coordination type organic nanotube |
EP2285345A1 (en) | 2008-05-15 | 2011-02-23 | Novartis AG | Pulmonary delivery of a fluoroquinolone |
EP3552602A1 (en) | 2009-03-18 | 2019-10-16 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
WO2010111641A2 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
US20100310660A1 (en) * | 2009-06-08 | 2010-12-09 | Taipei Medical University | Dry powder microparticles for pulmonary delivery |
KR101214778B1 (en) | 2009-10-01 | 2012-12-21 | 주식회사 바이오드 | Method for the intracellular transduction of viral vectors using complex of Fe cation / viral vectors |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
PT2621488T (en) | 2010-09-29 | 2019-02-12 | Pulmatrix Operating Co Inc | Cationic dry powders |
CN107096014B (en) | 2010-09-29 | 2022-07-15 | 普马特里克斯营业公司 | Monovalent metal cation dry powder for inhalation |
PT3590949T (en) | 2010-10-01 | 2022-08-02 | Modernatx Inc | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
JOP20120023B1 (en) | 2011-02-04 | 2022-03-14 | Novartis Ag | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
AU2012351947B2 (en) | 2011-12-16 | 2017-08-17 | Novartis Ag | Aerosolization apparatus for inhalation profile-independent drug delivery |
CN107596518B (en) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | Inhalable dry powder |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP3505176A1 (en) | 2012-04-02 | 2019-07-03 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
US20140199436A1 (en) * | 2013-01-15 | 2014-07-17 | Glanbia Nutritionals (Ireland) Ltd. | Method for Improving Viscosity, Solubility, and Particle Size of Milk Protein Concentrates |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
CN105209013B (en) | 2013-03-14 | 2019-04-26 | 诺华股份有限公司 | Spray dried formulations are decrystallized through taking off for mixing by spraying |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
EP2981247B1 (en) | 2013-04-01 | 2023-06-07 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
ES2762806T3 (en) | 2014-02-10 | 2020-05-25 | Respivant Sciences Gmbh | Treatment using mast cell stabilizers for systemic disorders |
CA2938996A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the treatment of lung diseases with mast cell stabilizers |
JP6701086B2 (en) * | 2014-02-20 | 2020-05-27 | オティトピック インコーポレイテッド | Dry powder formulation for inhalation |
JP6850524B2 (en) * | 2014-07-31 | 2021-03-31 | オティトピック インク. | Dry powder formulation for inhalation |
DK3212212T3 (en) | 2014-10-31 | 2020-12-21 | Univ Monash | POWDER FORMULATION |
US9968125B2 (en) | 2015-01-09 | 2018-05-15 | Philip Morris Products S.A. | Nicotine—diketopiperazine microparticle formulations and methods of making the same |
WO2016142708A2 (en) | 2015-03-10 | 2016-09-15 | Cipla Limited | Pharmaceutical composition |
EP3268010B1 (en) | 2015-03-11 | 2021-12-08 | University of Cincinnati | Compositions comprising acidified nitrite, an iron chelator and an antibiotic agent for use in the treatment of bacterial infections |
US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US11224594B2 (en) | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
US9585835B1 (en) | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
US10149844B2 (en) | 2015-09-16 | 2018-12-11 | Philip Morris Products S.A. | Inhalable nicotine formulations, and methods of making and using thereof |
US20170071248A1 (en) | 2015-09-16 | 2017-03-16 | Sansa Corporation (Barbados) Inc. | System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations |
US10849920B2 (en) | 2015-10-05 | 2020-12-01 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
AU2017208857B2 (en) | 2016-01-19 | 2019-11-14 | Novartis Ag | Multidose inhaler |
US10010294B2 (en) | 2016-02-01 | 2018-07-03 | Incarda Therapeutics, Inc. | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
KR101938870B1 (en) * | 2016-05-04 | 2019-04-10 | 고려대학교 산학협력단 | Si@CaCO3 microparticles as biohybrid materials for Separation and Purification |
EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
JP2019531308A (en) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | Cromolyn composition for the treatment of pulmonary fibrosis |
MX2019010263A (en) * | 2017-03-07 | 2019-10-09 | Philip Morris Products Sa | Inhalable nicotine formulations, and methods of making and using thereof. |
CA3060702A1 (en) | 2017-05-10 | 2018-11-15 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
BR112019026230A2 (en) | 2017-06-12 | 2020-06-30 | Novartis Ag | amorphous nanostructured pharmaceutical materials |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
EP3910324A1 (en) * | 2018-08-07 | 2021-11-17 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
CN109350747B (en) * | 2018-10-31 | 2022-03-01 | 南京医科大学 | ZL006 cyclohexyl polymer nano drug delivery system and preparation method thereof |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
EP4196105A1 (en) | 2020-08-14 | 2023-06-21 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate |
EP4304582A1 (en) | 2021-03-12 | 2024-01-17 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
WO2023158286A1 (en) * | 2022-02-21 | 2023-08-24 | 주식회사 툴바이오 | Calsequestrin-based metal ion reactive particle and uses thereof |
Family Cites Families (593)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE471490C (en) | 1931-08-12 | Karl Zeyen | Device for atomizing flour-like substances | |
US979993A (en) | 1910-03-24 | 1910-12-27 | Joseph Francis O'byrne | Projectile. |
US1855591A (en) | 1926-02-03 | 1932-04-26 | Wallerstein Co Inc | Invertase preparation and method of making the same |
US2457036A (en) | 1946-04-10 | 1948-12-21 | Albert A Epstein | Coffee concentrate and the process of producing it |
US2797201A (en) | 1953-05-11 | 1957-06-25 | Standard Oil Co | Process of producing hollow particles and resulting product |
BE556587A (en) | 1957-01-31 | 1957-04-11 | ||
DE1080265B (en) | 1958-09-30 | 1960-04-21 | Bayer Ag | Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances |
US3362405A (en) | 1964-04-06 | 1968-01-09 | Hamilton O. Hazel | Method and apparatus for admixing gas with solid particles |
US3619294A (en) | 1968-07-15 | 1971-11-09 | Penick & Ford Ltd | Method of combining crystalline sugar with impregnating agents and products produced thereby |
US3555717A (en) | 1968-10-24 | 1971-01-19 | Victor Comptometer Corp | Artificial fishing lure |
DE1812574A1 (en) | 1968-12-04 | 1970-06-11 | Riedel De Haen Ag | Process for the production of biocidal granules |
GB1263780A (en) | 1969-05-13 | 1972-02-16 | Matsushita Electric Ind Co Ltd | Piezoelectric ceramic compositions |
US3632357A (en) | 1969-07-29 | 1972-01-04 | Standard Brands Inc | Method of producing hard candy |
US3655442A (en) | 1969-08-27 | 1972-04-11 | California & Hawaiian Sugar | Method of making sugar and sugar products |
GB1265615A (en) | 1970-09-10 | 1972-03-01 | ||
US3975512A (en) | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
GB1410588A (en) | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
US3745682A (en) | 1971-09-28 | 1973-07-17 | Pneu Dart Inc | Gun for propelling a drug or medicine projectile |
US3811124A (en) | 1972-06-12 | 1974-05-14 | Ibm | Solid state gas panel display circuits with non-inductive solid state isolation between low level logic and high level drive signal functions |
DE2246013A1 (en) | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | PROCESS FOR THE MANUFACTURING OF POROUS TABLETS |
US3812854A (en) | 1972-10-20 | 1974-05-28 | A Michaels | Ultrasonic nebulizer |
FR2238476A1 (en) | 1973-07-23 | 1975-02-21 | Aries Robert | Double esters of zeranol and natural hormones - and their implants for livestock, have protein anabolism props |
US3957964A (en) | 1974-01-30 | 1976-05-18 | Colgate-Palmolive Company | Dentifrice containing encapsulated flavoring |
DE2415159A1 (en) | 1974-03-29 | 1975-10-09 | Hoechst Ag | SPRAY PRODUCTS CONTAINING ALKALINE CANSULFONATE AND METHOD FOR THEIR MANUFACTURING |
US3948263A (en) | 1974-08-14 | 1976-04-06 | Minnesota Mining And Manufacturing Company | Ballistic animal implant |
JPS5134879A (en) | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
US3964483A (en) | 1975-01-13 | 1976-06-22 | Syntex Puerto Rico, Inc. | Inhalation device |
US4005711A (en) | 1975-01-13 | 1977-02-01 | Syntex Puerto Rico, Inc. | Inhalation device |
FR2299011A1 (en) | 1975-01-29 | 1976-08-27 | Obert Jean Claude | PART AEROSOL GENERATOR |
US4102999A (en) | 1975-02-10 | 1978-07-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Process for producing stable macromomycin powder |
US4161516A (en) | 1975-07-25 | 1979-07-17 | Fisons Limited | Composition for treating airway disease |
JPS5733509Y2 (en) | 1976-04-19 | 1982-07-23 | ||
US4147766A (en) | 1976-06-09 | 1979-04-03 | Armour Pharmaceutical Company | Macrospherical particles of anti-perspirants |
GB1533012A (en) | 1976-12-20 | 1978-11-22 | Lloyd C | Confectionery machines |
NL7704348A (en) | 1977-04-21 | 1978-10-24 | Philips Nv | PROCEDURE FOR PREPARING A ATTENUATED TRANSMISSIBLE GASTROENTERITIS (TGE) VIRUS FOR USE IN LIVE VACCINES. |
US4180593A (en) | 1977-04-29 | 1979-12-25 | Cohan Allan N | Process for producing round spherical free flowing blown bead food products of controlled bulk density |
US4127502A (en) | 1977-06-10 | 1978-11-28 | Eastman Kodak Company | Stabilizers for reconstituted, lyophilized samples |
US4211769A (en) | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
JPS5492951A (en) | 1977-12-29 | 1979-07-23 | Shionogi & Co Ltd | Novel aminoglycoside derivative |
US4244949A (en) | 1978-04-06 | 1981-01-13 | The Population Council, Inc. | Manufacture of long term contraceptive implant |
IT1108132B (en) | 1978-07-12 | 1985-12-02 | Fiat Trattori Spa | DEVICE SUITABLE TO IMPROVE THE CONTROL OF TOOLS CARRIED BY AGRICULTURAL TRACTORS |
US4158544A (en) | 1978-07-17 | 1979-06-19 | Beckman Instruments, Inc. | Process for preparing a biological composition for use as a reference control in diagnostic analysis |
US4253468A (en) | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
US4588744A (en) | 1978-09-19 | 1986-05-13 | Mchugh John E | Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide |
GB2037735B (en) | 1978-12-21 | 1983-11-09 | Standard Telephones Cables Ltd | Glass composition |
EP0015123B1 (en) | 1979-02-21 | 1982-12-22 | Imperial Chemical Industries Plc | A process for the extraction of poly-3-hydroxy-butyric acid from microbial cells |
US4281031A (en) | 1979-07-25 | 1981-07-28 | Machine Technology, Inc. | Method and apparatus for processing workpieces |
GB2065659A (en) * | 1979-12-21 | 1981-07-01 | Nattermann A & Cie | Calciumphosphatidylchlorine- chloride, process for producing the same and pharmaceutical preparations containing the same |
DE2952115C2 (en) * | 1979-12-22 | 1982-05-06 | A. Nattermann & Cie GmbH, 5000 Köln | Rosmarinic acid phospholipid complex |
US4452239A (en) | 1980-03-25 | 1984-06-05 | Hilal Malem | Medical nebulizing apparatus |
EP0111216A3 (en) | 1980-03-31 | 1985-01-16 | Takeda Chemical Industries, Ltd. | Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor |
US4326524A (en) | 1980-09-30 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Solid dose ballistic projectile |
US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
JPS5795920A (en) | 1980-12-04 | 1982-06-15 | Teijin Ltd | Remedy for respiratory disease |
SE439599B (en) | 1981-01-14 | 1985-06-24 | Kema Nord Ab | WAY TO DRY AND EXPAND IN LIQUID DISPERSED, THERMOPLASTIC MICROSPHERES CONTAINING, VOLTABLE, LIQUID JEWELERY |
US4371557A (en) | 1981-01-21 | 1983-02-01 | General Foods Corporation | Maintenance of protein quality in foods containing reducing sugars |
ATE15901T1 (en) | 1981-01-21 | 1985-10-15 | Unilever Nv | SUBSTANCE CONTAINING LIPIDS AND PROTEINS IN PARTICULATE FORM AND PROCESS FOR ITS MANUFACTURE. |
US5366734A (en) | 1981-02-16 | 1994-11-22 | Zeneca Limited | Continuous release pharmaceutical compositions |
US4327077A (en) | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
DE3274065D1 (en) | 1981-07-08 | 1986-12-11 | Draco Ab | POWDER INHALATOR |
US4484577A (en) | 1981-07-23 | 1984-11-27 | Key Pharmaceuticals, Inc. | Drug delivery method and inhalation device therefor |
DE3268533D1 (en) | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
US5260306A (en) | 1981-07-24 | 1993-11-09 | Fisons Plc | Inhalation pharmaceuticals |
GB2105189B (en) | 1981-07-24 | 1985-03-20 | Fisons Plc | Inhalation drugs |
KR890000664B1 (en) | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | Preparation method for micronised be clomethasone dispropionate mono-hydrate |
DE3141498A1 (en) | 1981-10-20 | 1983-04-28 | Bayer Ag, 5090 Leverkusen | Pharmaceutical containing kallikrein and process for its preparation |
US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
JPS58164683A (en) | 1982-03-25 | 1983-09-29 | Takeda Chem Ind Ltd | Stabilized solid composition |
US4659696A (en) | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
JPS58216695A (en) | 1982-06-07 | 1983-12-16 | Otsuka Shokuhin Kogyo Kk | Preparation of trehalose |
JPS58215695A (en) | 1982-06-09 | 1983-12-15 | 株式会社デンソー | Electric alarm |
US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
CA1221689A (en) | 1982-09-10 | 1987-05-12 | Mark E. Thompson | Herbicidal ortho-alkyl- and ortho-alkenyl-substituted benzenesulfonamides |
US4591552A (en) | 1982-09-29 | 1986-05-27 | New York Blood Center, Inc. | Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide |
JPS5995885U (en) | 1982-12-17 | 1984-06-29 | 日本擬餌鈎工業株式会社 | Uki |
ES519619A0 (en) | 1983-02-08 | 1984-03-16 | Gandariasbeitia Aguirreche Man | CONTINUOUS PROCEDURE FOR THE PRODUCTION OF PROTEOLYTIC AND AMINOLYTIC ENZYMES FROM VEGETABLE MICROORGANISMS. |
JPS59163313A (en) | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
JPS59168679U (en) | 1983-04-27 | 1984-11-12 | 三菱重工業株式会社 | air conditioner |
US4883762A (en) | 1983-06-06 | 1989-11-28 | Ciba Corning Diagnostics Corp. | Stabilized isoenzyme control products |
JPS6035263A (en) | 1983-08-05 | 1985-02-23 | Wako Pure Chem Ind Ltd | Stabilization of immunologically active substance immobilized on non-soluble carrier and physiologically active substance measuring reagent containing the same as composition unit |
US4865871A (en) | 1983-08-23 | 1989-09-12 | Board Of Regents The University Of Texas System | Method for cryopreparing biological tissue |
GB8323094D0 (en) | 1983-08-26 | 1983-09-28 | Franks F | Preservation of cells |
DE3484951D1 (en) | 1983-10-14 | 1991-09-26 | Sumitomo Pharma | EXTENDED PREPARATIONS WITH DELAYED DELIVERY. |
ATE93384T1 (en) | 1983-11-14 | 1993-09-15 | Univ Kentucky Res Found | POROUS MICROBALLS FOR DRUG DELIVERY AND PROCESS FOR THEIR MANUFACTURE. |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4534343A (en) | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
GB2187191B (en) | 1984-01-30 | 1989-11-01 | Quadrant Bioresources Ltd | Protection of proteins and the like |
US4758583A (en) | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
DD238305A3 (en) | 1984-04-23 | 1986-08-20 | Maisan Werke Barby Veb | PROCESS FOR THE PREPARATION OF D-GLUCOSE AND STAERKEHYDROLYSATES |
US4617272A (en) | 1984-04-25 | 1986-10-14 | Economics Laboratory, Inc. | Enzyme drying process |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
JPS60244288A (en) | 1984-05-18 | 1985-12-04 | Ookura Seiyaku Kk | Preparation of stable serrapeptase powder |
JPH0239237B2 (en) | 1984-05-21 | 1990-09-04 | Noda Sangyo Kagaku Kenkyusho | SHUSANOKISHIDAAZENOSEIZOHO |
US4620847A (en) | 1984-06-01 | 1986-11-04 | Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh Polimerov | Device for administering powdered substances |
JPS60258195A (en) | 1984-06-05 | 1985-12-20 | Ss Pharmaceut Co Ltd | Alpha,alpha-trehalose fatty acid diester derivative and its preparation |
JPS60258125A (en) | 1984-06-06 | 1985-12-20 | Hayashibara Biochem Lab Inc | Water-soluble dried material containing proteinic physiologically active substance |
US4721709A (en) | 1984-07-26 | 1988-01-26 | Pyare Seth | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions |
GB8421282D0 (en) | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
US4971787A (en) | 1984-08-27 | 1990-11-20 | Warner-Lambert Company | Antacid chewing gum |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
DE3445010A1 (en) | 1984-12-10 | 1986-06-19 | Boehringer Mannheim Gmbh | CONTROL OR OAK SERUM FOR LIPID DIAGNOSTICS |
GB8500698D0 (en) | 1985-01-11 | 1985-02-13 | Unilever Plc | Preparation of reagents |
FR2575923B1 (en) | 1985-01-15 | 1988-02-05 | Jouveinal Sa | LACTULOSE-BASED LAXATIVE COMPOSITION, AND METHOD FOR THE PRODUCTION THEREOF |
US4830858A (en) | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US4942544A (en) | 1985-02-19 | 1990-07-17 | Kenneth B. McIntosh | Medication clock |
GB8508173D0 (en) | 1985-03-28 | 1985-05-01 | Standard Telephones Cables Ltd | Controlled delivery device |
FR2580087B1 (en) | 1985-04-03 | 1988-12-02 | Hispano Suiza Sa | |
EP0229810B1 (en) | 1985-07-09 | 1991-10-16 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
FR2586587B1 (en) | 1985-08-30 | 1987-10-23 | Adir | NEW ARTIFICIAL SURFACTANTS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
NZ217645A (en) | 1985-09-25 | 1991-11-26 | Oncogen | Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations |
US4680027A (en) | 1985-12-12 | 1987-07-14 | Injet Medical Products, Inc. | Needleless hypodermic injection device |
JPS62174094A (en) | 1985-12-16 | 1987-07-30 | Ss Pharmaceut Co Ltd | Alpha, alpha-trehalose derivative and production thereof |
JPH0710344B2 (en) | 1985-12-26 | 1995-02-08 | 株式会社林原生物化学研究所 | Method for dehydrating hydrated substance by anhydrous glycosyl fructose |
DE3600567C1 (en) | 1986-01-10 | 1987-05-07 | Automatik App Maschb Gmbh | Device for granulating struts made of thermoplastic materials |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
GB8604983D0 (en) | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
SE453566B (en) | 1986-03-07 | 1988-02-15 | Draco Ab | POWDER INHALATOR DEVICE |
JPS62228272A (en) | 1986-03-27 | 1987-10-07 | Amano Pharmaceut Co Ltd | Stable peroxidase formulation |
US5017372A (en) | 1986-04-14 | 1991-05-21 | Medicis Corporation | Method of producing antibody-fortified dry whey |
IL82245A (en) | 1986-04-25 | 1990-07-26 | Basf Ag | Preparation of spray-dried granules of active ingredients |
JPH0655678B2 (en) | 1986-04-26 | 1994-07-27 | 不二製油株式会社 | Oligopeptide infusion |
US4739754A (en) | 1986-05-06 | 1988-04-26 | Shaner William T | Suction resistant inhalator |
US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
US4762857A (en) | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
ATE76311T1 (en) | 1986-08-19 | 1992-06-15 | Genentech Inc | DEVICE AND DISPERSION FOR INTRAPULMONARY DELIVERY OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINES. |
SE8603812D0 (en) | 1986-09-12 | 1986-09-12 | Draco Ab | ADMINISTRATION OF LIPOSOMES TO MAMMALS |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
DE3636669C2 (en) | 1986-10-28 | 2001-08-16 | Siemens Ag | Arrangement for delivering aerosol to a patient's airways and / or lungs |
US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US4851211A (en) | 1986-11-25 | 1989-07-25 | Abbott Laboratories | LHRH analog formulations |
US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US5032585A (en) | 1987-02-17 | 1991-07-16 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
US5089181A (en) | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
FR2611501B1 (en) | 1987-03-04 | 1991-12-06 | Corbiere Jerome | NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ROUTE BASED ON LYSINE ACETYLSALIELYLATE AND PROCESS FOR OBTAINING SAME |
CA1337268C (en) | 1987-03-09 | 1995-10-10 | Edmund P. Bass | Canine distemper virus vaccine |
US5718921A (en) | 1987-03-13 | 1998-02-17 | Massachusetts Institute Of Technology | Microspheres comprising polymer and drug dispersed there within |
US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US5387431A (en) | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
JP2656944B2 (en) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | Aerosolization of protein therapeutics |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
GB8712176D0 (en) | 1987-05-22 | 1987-06-24 | Cosmas Damian Ltd | Drug delivery system |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5571499A (en) | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5069936A (en) | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
GB8715238D0 (en) | 1987-06-29 | 1987-08-05 | Quadrant Bioresources Ltd | Food process |
US5240712A (en) | 1987-07-17 | 1993-08-31 | The Boots Company Plc | Therapeutic agents |
US5043158A (en) | 1987-08-21 | 1991-08-27 | Chembiomed, Ltd. | Immunogenic compositions containing ordered carriers |
CA1327161C (en) | 1987-09-01 | 1994-02-22 | Mitsugu Kobayashi | Lyophilized pharmaceutical composition of neocarzinostatin derivative |
GB8722622D0 (en) | 1987-09-25 | 1987-11-04 | Halo Retail Systems Ltd | Dot-matrix printers |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
EP0325936A3 (en) | 1988-01-16 | 1990-01-17 | Ono Pharmaceutical Co., Ltd. | Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients |
GB8801338D0 (en) | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
GB8802174D0 (en) | 1988-02-01 | 1988-03-02 | Quadrant Bioresources Ltd | Method of drying macromolecules |
DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
US5045446A (en) | 1988-08-26 | 1991-09-03 | Cryopharm Corporation | Lyophilization of cells |
US4950477A (en) | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
US5049664A (en) | 1988-08-26 | 1991-09-17 | Sawai Pharmaceutical Co., Ltd. | Trehalose derivatives |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
EP0360340A1 (en) | 1988-09-19 | 1990-03-28 | Akzo N.V. | Composition for nasal administration containing a peptide |
JP2733259B2 (en) | 1988-09-20 | 1998-03-30 | 旭化成工業株式会社 | Porous microcellulose particles |
IT1230508B (en) | 1988-10-11 | 1991-10-25 | Italiana Sali C I S S P A Comp | SELF-DISPERSING COMPOSITION IN WATER PARTICULARLY SUITABLE FOR TREATMENT OF THE SKIN |
US4984158A (en) | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
GB8824897D0 (en) | 1988-10-24 | 1988-11-30 | Ici Plc | Biocatalysts |
GB8826429D0 (en) | 1988-11-11 | 1988-12-14 | Univ Leeds Ind Service Ltd | Enzyme stabilisation systems |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5043165A (en) | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5006343A (en) | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
CA2008176A1 (en) | 1989-01-25 | 1990-07-25 | John W. Palmour | Silicon carbide schottky diode and method of making same |
US5011678A (en) | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
IT1228459B (en) | 1989-02-23 | 1991-06-19 | Phidea S R L | INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE. |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
FR2645021A1 (en) | 1989-03-30 | 1990-10-05 | Sanofi Sa | USE OF A POTASSIC AGONIST IN THE TREATMENT OF GLAUCOMA |
AU5414990A (en) | 1989-04-12 | 1990-11-05 | Aberdeen University | Slow release vitreous systems |
US5270048A (en) | 1989-04-21 | 1993-12-14 | Borden (Uk) Limited | Controlled delivery devices |
EP0432232B1 (en) | 1989-05-01 | 1994-01-05 | Alkermes Controlled Therapeutics, Inc. | Process for producing small particles of biologically active molecules |
US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
US5069786A (en) | 1989-06-15 | 1991-12-03 | Cuno, Incorporated | Filter apparatus snap lock cartridge retainer |
FI84698C (en) | 1989-06-16 | 1992-01-10 | Huhtamaeki Oy | ANORDINATION FOR FINANCING OF AGGLOMERIA AV EN ENKELDOS AV ETT LAEKEMEDELPREPARAT I PULVERFORM. |
JP2783848B2 (en) * | 1989-07-04 | 1998-08-06 | 晟 八木 | New phosphatidylcholine calcium and its manufacturing method |
US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
GB8917470D0 (en) | 1989-07-31 | 1989-09-13 | Quadrant Bioresources Ltd | Composition and method |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5562608A (en) | 1989-08-28 | 1996-10-08 | Biopulmonics, Inc. | Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation |
US5208226A (en) | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
FR2651680B1 (en) | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES. |
GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
FR2652497A1 (en) | 1989-09-29 | 1991-04-05 | Mendolia Georges | FEMORO-PATELLAR PROSTHESIS AND ITS SETTING DEVICES. |
US5013557A (en) | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
IT1237118B (en) | 1989-10-27 | 1993-05-18 | Miat Spa | MULTI-DOSE INHALER FOR POWDER DRUGS. |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
JPH03161441A (en) | 1989-11-20 | 1991-07-11 | Senjiyu Seiyaku Kk | Maillard reaction inhibitor |
JP2854631B2 (en) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | Prevention and treatment of diabetic complications and diseases caused by aging |
GB8926643D0 (en) | 1989-11-24 | 1990-01-17 | Unilever Plc | Cleaning composition |
KR970007917B1 (en) | 1989-11-28 | 1997-05-17 | 신텍스 인크. | New tricyclic compounds |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
NL9000207A (en) | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Aerosol propellant compositions |
ATE129152T1 (en) | 1990-02-19 | 1995-11-15 | Senju Pharma Co | COMPOSITIONS OF MAILLARD REACTION INHIBITORS. |
FR2658418B1 (en) | 1990-02-20 | 1994-09-02 | Synthelabo | PHARMACEUTICAL COMPOSITIONS BASED ON PHOSPHOLIPIDS. |
GB9003821D0 (en) | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
CA2036844A1 (en) | 1990-02-22 | 1991-08-23 | Hua-Pin Huang | Procaterol microspheres controlled-release aerosol |
US5925337A (en) | 1990-03-01 | 1999-07-20 | L'oreal | Waterproof composition for covering the eyelashes, and process for the preparation thereof |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
JP2859919B2 (en) | 1990-03-15 | 1999-02-24 | 旭化成工業株式会社 | Method for improving dissolution of poorly soluble drugs |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5312909A (en) | 1990-03-28 | 1994-05-17 | Gist Brocades, N.V. | Recombinant DNA encoding neutral trehalase |
IN172208B (en) | 1990-04-02 | 1993-05-01 | Sint Sa | |
JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
ATE145244T1 (en) * | 1990-04-17 | 1996-11-15 | Liposome Co Inc | ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES FROM PHOSPHOLIPIDES |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5145369A (en) | 1990-04-23 | 1992-09-08 | L. Paul Lustig | Dental tool driving apparatus having rotating and roto-reciprocating motions |
WO1991016882A1 (en) | 1990-05-08 | 1991-11-14 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
GB9010742D0 (en) | 1990-05-14 | 1990-07-04 | Quadrant Bioresources Ltd | Stabilization of biological macromolecular substances |
US5621094A (en) | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
GB9012663D0 (en) | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
WO1992000062A1 (en) | 1990-06-27 | 1992-01-09 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
PT98105B (en) | 1990-06-28 | 1998-11-30 | Glaxo Inc | PROCESS FOR THE PREPARATION OF FORMULATIONS IN AEROSOL CONTAINING AS PROPULSOR 1,1,1,2-TETRAFLUOROETHANE |
AU8055691A (en) | 1990-06-29 | 1992-01-23 | Fisons Plc | Pressurised aerosol compositions |
IT1246350B (en) | 1990-07-11 | 1994-11-17 | Eurand Int | METHOD FOR OBTAINING A RAPID SUSPENSION OF INSOLUBLE DRUGS IN WATER |
DE69130708T2 (en) | 1990-07-19 | 1999-05-27 | Us Commerce | IMPROVED IMMUNOTHERAPEUTIC METHOD FOR PREVENTING OR TREATING VIRAL DISEASES OF THE respiratory tract |
JPH06500632A (en) | 1990-08-10 | 1994-01-20 | アナリティカル・コントロール・システムズ・インコーポレーテッド | Improved diagnostic and therapeutic compositions |
US4999384A (en) | 1990-08-14 | 1991-03-12 | General Electric Company | Foamed blends of nylon 6,I/T and polycarbonate |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
US5200399A (en) | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
FR2667072B1 (en) * | 1990-09-24 | 1993-08-13 | Bioetica Sa | TERNARY COMPLEX OF CHITOSANE, CALCIUM IONS AND LIPIDS, METHOD OF PREPARATION AND THEIR APPLICATIONS. |
US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5173298A (en) | 1990-09-27 | 1992-12-22 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5304125A (en) | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
CA2094266C (en) | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
GB9024365D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
WO1992011050A1 (en) | 1990-12-17 | 1992-07-09 | Minnesota Mining And Manufacturing Company | Inhaler |
JPH04230625A (en) | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | Method for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating |
EP0495187B1 (en) | 1991-01-15 | 1997-01-22 | Hemosphere, Inc. | Protein nanomatrixes and method of production |
US5616311A (en) | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1992014697A1 (en) | 1991-02-08 | 1992-09-03 | Cambridge Neuroscience, Inc. | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
ATE179605T1 (en) | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION |
US5182097A (en) | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
WO1992014449A1 (en) | 1991-02-20 | 1992-09-03 | Nova Pharmaceutical Corporation | Controlled release microparticulate delivery system for proteins |
US5450336A (en) | 1991-03-05 | 1995-09-12 | Aradigm Corporation | Method for correcting the drift offset of a transducer |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
AU6130594A (en) | 1991-03-05 | 1994-08-15 | Miris Medical Corporation | Method and device for correcting the drift offset of a pressure sensor of a flowmeter |
NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
DE59107894D1 (en) | 1991-03-21 | 1996-07-11 | Ritzau Pari Werk Gmbh Paul | Nebulizers, in particular for use in devices for inhalation therapy |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
SE9101090D0 (en) | 1991-04-11 | 1991-04-11 | Astra Ab | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES |
US5437272A (en) | 1991-05-01 | 1995-08-01 | Alliance Pharmaceutical Corp. | Perfluorocarbon associated gas exchange |
DK0583358T3 (en) | 1991-05-03 | 1999-08-16 | Alliance Pharma | Partial fluid respiration of carbon fluorides |
DK0512916T3 (en) | 1991-05-07 | 1999-09-20 | Liposome Co Inc | Liposomal prostaglandin formulations |
US6060069A (en) | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
CZ271393A3 (en) | 1991-06-10 | 1994-07-13 | Schering Corp | Aerosol preparations without chlorofluorinated hydrocarbons |
HUT67449A (en) | 1991-06-10 | 1995-04-28 | Schering Corp | Aerosol formulations containing 1,1,1,2,3,3,3-heptafluoropropane |
AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
US6681767B1 (en) | 1991-07-02 | 2004-01-27 | Nektar Therapeutics | Method and device for delivering aerosolized medicaments |
DE69230613T2 (en) | 1991-07-02 | 2000-12-28 | Inhale Inc | METHOD AND DEVICE FOR DISPENSING MEDICINES IN AEROSOL FORM |
JPH06511481A (en) | 1991-07-05 | 1994-12-22 | ユニバーシティ オブ ロチェスター | Ultra-fine non-agglomerated porous particles that incorporate air bubbles |
KR100229675B1 (en) | 1991-07-31 | 1999-11-15 | 머즈피터 | Grinder for grinding a cylinderical or spherical of a roll, especially a paper machine roll |
GB9116610D0 (en) | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
TW221689B (en) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
GB9120005D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
GB9123953D0 (en) | 1991-11-12 | 1992-01-02 | Minnesota Mining & Mfg | Inhalation device |
CA2123494A1 (en) | 1991-11-14 | 1993-05-27 | Ernest G. Schutt | Method and apparatus for partial liquid ventilation using fluorocarbons |
ES2090714T3 (en) | 1991-12-05 | 1996-10-16 | Mallinckrodt Veterinary Inc | CARBOHYDRATE GLASS MATRIX FOR THE PROLONGED RELEASE OF A THERAPEUTIC AGENT. |
DE4140689B4 (en) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalable powders and process for their preparation |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5674471A (en) | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
US5736124A (en) | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5744123A (en) | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5683676A (en) | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
ATE171865T1 (en) | 1991-12-12 | 1998-10-15 | Glaxo Group Ltd | DRUG |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
ATE128350T1 (en) | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | PHARMACEUTICAL AEROSOL FORMULATION. |
EP0625207A1 (en) | 1991-12-17 | 1994-11-23 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
CA2083676A1 (en) | 1991-12-17 | 1993-06-18 | Paul E. Naton | Compositions containing hollow microspheres |
ES2159678T3 (en) * | 1991-12-18 | 2001-10-16 | Minnesota Mining & Mfg | AEROSOL FORMULATIONS IN SUSPENSION. |
US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
FR2685857A1 (en) | 1992-01-06 | 1993-07-09 | Jean Marcel | Aerosol can containing microcapsules |
ATE146359T1 (en) | 1992-01-21 | 1997-01-15 | Stanford Res Inst Int | IMPROVED METHOD FOR PRODUCING MICRONIZED POLYPEPTIDE DRUGS |
GB9202519D0 (en) | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
RU94040856A (en) | 1992-03-03 | 1996-08-20 | Дайити Фармасьютикал Ко. | Vaccine for oral administration |
CA2131285C (en) | 1992-03-10 | 2004-06-29 | Lewis James Baskeyfield | Pharmaceutical inhalation compositions |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
AU2088992A (en) | 1992-05-05 | 1993-11-11 | Research Foundation For Microbial Diseases Of Osaka University, The | Stabilized live vaccine |
IT1254359B (en) | 1992-05-11 | 1995-09-14 | Serono Cesare Ist Ricerca | PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6 |
NL9200844A (en) | 1992-05-13 | 1993-12-01 | De Wijdeven Gijsbertus G P Van | DEVICE AND METHOD FOR INJECTING WITH A SOLID SUBSTANCE. |
US5292513A (en) | 1992-05-18 | 1994-03-08 | Anthony G. Gristina | Method for nonspecific cellular immune stimulation |
US5215079A (en) | 1992-05-19 | 1993-06-01 | Armstrong Pharmaceuticals, Inc. | Single dose metered dose inhaler for delivery of vaccines and other drugs |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
ES2177544T3 (en) | 1992-06-12 | 2002-12-16 | Teijin Ltd | ULTRAFININE POWDER TO INHALATE AND METHOD FOR PREPARATION. |
GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
US5376359A (en) | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6673335B1 (en) | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
MX9304585A (en) | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN. |
GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
US5239993A (en) | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
DK0679088T3 (en) | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonary delivery of active fragments of parathyroid hormone |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
CA2147260C (en) | 1992-10-19 | 1999-04-13 | Mark Bernard Mecikalski | Dry powder inhaler |
US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
US5422384A (en) | 1992-11-25 | 1995-06-06 | Battelle Memorial Institute | Glass/polymer composites and methods of making |
JP3168550B2 (en) | 1992-12-02 | 2001-05-21 | 株式会社林原生物化学研究所 | Dehydrating agent, method for dehydrating hydrated material using the same, and dehydrated article obtained by the method |
CA2150803C (en) | 1992-12-02 | 2006-01-31 | Henry Auer | Controlled release growth hormone containing microspheres |
SE9203743D0 (en) | 1992-12-11 | 1992-12-11 | Astra Ab | EFFICIENT USE |
US5453514A (en) | 1992-12-25 | 1995-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors |
EP0678034B1 (en) | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
JP3264537B2 (en) | 1993-01-22 | 2002-03-11 | キヤノン株式会社 | Communication device and control method thereof |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US6131567A (en) | 1993-01-29 | 2000-10-17 | Aradigm Corporation | Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
RU2075700C1 (en) | 1993-02-16 | 1997-03-20 | Казанский инженерно-строительный институт | Ventilation shelter |
ES2153418T3 (en) | 1993-02-23 | 2001-03-01 | Genentech Inc | STABILIZATION OF POLYPEPTIDES TREATED WITH ORGANIC SOLVENTS THROUGH EXCIPIENTS. |
US5437274A (en) | 1993-02-25 | 1995-08-01 | Gholam A. Peyman | Method of visualizing submicron-size vesicles and particles in blood circulation |
AU679511B2 (en) | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US20020132787A1 (en) | 1993-04-07 | 2002-09-19 | Mohammed Eljamal | Compositions and methods for nucleic acid delivery to the lung |
DK42093D0 (en) | 1993-04-07 | 1993-04-07 | Bukh Meditec | METHOD OF ADMINISTRATION |
TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
US5492688A (en) | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
ES2068151B1 (en) | 1993-06-23 | 1995-11-16 | Cabrera Garrido Juan | INJECTABLE MICROS FOAM FOR SCLEROSIS. |
IS1796B (en) | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
GB9313650D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
GB9314886D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Production of a biological control agent |
SE9302550D0 (en) | 1993-07-30 | 1993-07-30 | Ernst Hoerlin | POWDER INHALES |
EP0711179B2 (en) | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
US5508203A (en) * | 1993-08-06 | 1996-04-16 | Fuller; Milton E. | Apparatus and method for radio frequency spectroscopy using spectral analysis |
GB9316745D0 (en) | 1993-08-12 | 1993-09-29 | Medeva Holdings Bv | Vaccine compositions |
EP0714314B1 (en) | 1993-08-18 | 1998-10-14 | FISONS plc | Inhalator with breath flow regulation |
AU4953393A (en) | 1993-08-24 | 1995-03-21 | Mogen International N.V. | Production of trehalose in plants |
US5470885A (en) | 1993-09-29 | 1995-11-28 | The Research Foundation Of The State University Of New York | Fluorocarbons as anti-inflammatory agents |
US5994318A (en) * | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
DE4334071C1 (en) | 1993-10-06 | 1995-02-09 | Siemens Ag | Process for reducing the nitrogen oxide concentration in the exhaust gas of an internal combustion engine or a combustion plant |
JP2828391B2 (en) | 1993-10-29 | 1998-11-25 | 東燃株式会社 | Liposomes with oligosaccharides on the surface |
EP0655237A1 (en) | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medicinal aerosol formulation |
CA2176249C (en) | 1993-12-02 | 2010-06-01 | Akwete L. Adjei | Aerosol drug formulations for use with non-cfc propellants |
DE69424181T2 (en) | 1993-12-20 | 2000-10-19 | Minnesota Mining & Mfg | FLUNISOLIDE AEROSOL FORMULATIONS |
JPH07203396A (en) | 1993-12-28 | 1995-08-04 | Sony Corp | Subtitle data decoding device |
PT101450B (en) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | NEW INHALATION DEVICE |
EP0802797A1 (en) | 1994-02-03 | 1997-10-29 | The Picower Institute For Medical Research | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5502092A (en) | 1994-02-18 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Biocompatible porous matrix of bioabsorbable material |
EP0748225B1 (en) | 1994-03-04 | 2004-06-09 | Genentech, Inc. | PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION |
ATE264096T1 (en) | 1994-03-07 | 2004-04-15 | Nektar Therapeutics | METHOD AND MEANS FOR ADMINISTERING INSULIN VIA THE LUNGS |
US20030113273A1 (en) | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
KR970701535A (en) | 1994-03-14 | 1997-04-12 | 지울리아노 페트렐리 | Aerosol drug formulations containing vitamin'E |
DE69527307T2 (en) | 1994-03-18 | 2003-03-20 | Kao Corp | POROUS FINE PARTICLES AND COSMETICS |
US5508023A (en) | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
GB2288732B (en) | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
GB9408053D0 (en) | 1994-04-22 | 1994-06-15 | Nat Heart & Lung Inst | Pharmaceutical preparation |
JP3993230B2 (en) | 1994-05-10 | 2007-10-17 | ワイス | Improved modified BRSV live vaccine |
CA2189351C (en) | 1994-05-13 | 2008-12-30 | Stephen J. Farr | Narcotic containing aerosol formulation |
DE69534318T2 (en) | 1994-05-18 | 2006-04-20 | Nektar Therapeutics, San Carlos | METHODS AND COMPOSITIONS FOR THE DRY PLANT FROM INTERFERONS |
GB9410222D0 (en) | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
ATE235919T1 (en) | 1994-06-02 | 2003-04-15 | Elan Drug Delivery Ltd | METHOD FOR PREVENTING AGGREGATION OF PROTEINS/PEPTIDES DURING REHYDRATION OR DEFROSTING |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
CA2126034A1 (en) | 1994-06-16 | 1995-12-17 | Amado Cordova | Potted fiber optic gyro sensor coil for stringent vibration and thermal environments |
US6142216A (en) | 1994-07-27 | 2000-11-07 | Bradford White Corporation | Indirect water heater |
US5591453A (en) | 1994-07-27 | 1997-01-07 | The Trustees Of The University Of Pennsylvania | Incorporation of biologically active molecules into bioactive glasses |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
DE69531992T2 (en) | 1994-08-04 | 2004-07-22 | Elan Drug Delivery Ltd., Ruddington | SOLID ADMINISTRATION SYSTEMS FOR THE TAXED RELEASE OF MOLECULARS BUILT IN IT AND METHOD FOR THE PRODUCTION THEREOF |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US5635159A (en) | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
BR9509201A (en) | 1994-09-09 | 1997-12-30 | Takeda Chemical Industries Ltd | Sustained release preparation using a polyvalent metal salt insoluble in water or slightly soluble in water and process to produce a sustained release preparation |
ATE387925T1 (en) | 1994-09-21 | 2008-03-15 | Nektar Therapeutics | DEVICE AND METHOD FOR DISPERSING DRY POWDER MEDICATIONS |
DE4434629C1 (en) | 1994-09-28 | 1996-06-27 | Byk Gulden Lomberg Chem Fab | IRDS and ARDS treatment compositions |
BR9509171A (en) | 1994-09-29 | 1997-09-16 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
US6117455A (en) | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
US5654278A (en) | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
US5547696A (en) | 1994-10-13 | 1996-08-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5631225A (en) | 1994-10-13 | 1997-05-20 | Novo Nordisk A/S | Pharmaceutical formulation |
US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5535089A (en) | 1994-10-17 | 1996-07-09 | Jing Mei Industrial Holdings, Ltd. | Ionizer |
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
JPH08157491A (en) | 1994-11-30 | 1996-06-18 | Hayashibara Biochem Lab Inc | Production of trehalose derivative |
ATE234080T1 (en) | 1994-12-16 | 2003-03-15 | Elan Drug Delivery Ltd | CROSS-LINKED MICROPARTICLES AND THEIR USE AS MEDICINAL CARRIERS |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
SA95160463B1 (en) | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | powders for inhalation |
HUT77775A (en) | 1994-12-22 | 1998-08-28 | Astra Aktiebolag | Aerosol drug formulations |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US5705482A (en) | 1995-01-13 | 1998-01-06 | Novo Nordisk A/S | Pharmaceutical formulation |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5962424A (en) | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
AU5417796A (en) | 1995-03-07 | 1996-09-23 | University Of Pittsburgh | A dry powder formulation for gene therapy |
DE19510690A1 (en) | 1995-03-14 | 1996-09-19 | Schering Ag | Polymeric nano- and / or microparticles, processes for their production, and use in medical diagnostics and therapy |
US5659297A (en) | 1995-03-27 | 1997-08-19 | Eaton Corporation | Display system |
US5653961A (en) | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5474059A (en) | 1995-04-08 | 1995-12-12 | Cooper; Guy F. | Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
CA2218074C (en) | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
GB9508691D0 (en) | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
US5770585A (en) | 1995-05-08 | 1998-06-23 | Kaufman; Robert J. | Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
DE19518196A1 (en) | 1995-05-22 | 1996-11-28 | Zahnradfabrik Friedrichshafen | Power steering for motor vehicles |
US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US6168804B1 (en) | 1995-06-07 | 2001-01-02 | University Of Alberta | Method for eliciting Th1-specific immune response |
US6129934A (en) | 1995-06-07 | 2000-10-10 | Ony, Inc. | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
WO1996040077A2 (en) | 1995-06-07 | 1996-12-19 | Quadrant Holdings Cambridge Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
JP4215820B2 (en) | 1995-06-07 | 2009-01-28 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Novel targeted compositions for diagnostic and therapeutic uses |
WO1996040277A2 (en) | 1995-06-07 | 1996-12-19 | Brown University Research Foundation | Spray dried polymeric microparticles containing imaging agents |
US6248720B1 (en) | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US5807552A (en) | 1995-08-04 | 1998-09-15 | Board Of Regents, The University Of Texas System | Compositions for conferring immunogenicity to a substance and uses thereof |
EP0862420A4 (en) | 1995-10-13 | 1999-11-03 | Penn State Res Found | Synthesis of drug nanoparticles by spray drying |
US6041777A (en) | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
US5955143A (en) | 1995-12-21 | 1999-09-21 | Drexel University | Hollow polymer microcapsules and method of producing the same |
AU725348B2 (en) | 1996-01-03 | 2000-10-12 | Glaxo Group Limited | Inhalation device |
US5740064A (en) | 1996-01-16 | 1998-04-14 | Hewlett-Packard Co. | Sampling technique for waveform measuring instruments |
DE19601430C1 (en) | 1996-01-17 | 1997-04-24 | Lohmann Therapie Syst Lts | Systemic treatment of plants with active agent |
ES2171883T3 (en) | 1996-01-24 | 2002-09-16 | Byk Gulden Lomberg Chem Fab | PROCEDURE FOR THE PREPARATION OF FORMULATIONS OF PULMONARY TENSIOACTIVE AGENTS IN DUST FORM. |
DE19602332A1 (en) | 1996-01-24 | 1997-07-31 | Byk Gulden Lomberg Chem Fab | Production of lung surfactant preparation in powder form |
JP3178724B2 (en) | 1996-03-05 | 2001-06-25 | エイカスフィアー・インコーポレーテッド | Microencapsulated fluorinated gas for use as an imaging agent |
US5611344A (en) | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
US5824133A (en) | 1996-03-12 | 1998-10-20 | Emr Microwave Technology Corporation | Microwave treatment of metal bearing ores and concentrates |
US5861175A (en) | 1996-03-15 | 1999-01-19 | Alliance Pharmaceutical Corp. | Use of fluorocarbons for diagnosis and treatment of articular disorders |
GB9605628D0 (en) | 1996-03-18 | 1996-05-22 | Univ North Wales | Apparatus for carrying out reactions |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
GB9607035D0 (en) | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
HUP9901575A3 (en) | 1996-04-29 | 1999-11-29 | Dura Pharmaceuticals Inc San D | Methods of dry powder inhalation |
EP0914096B1 (en) | 1996-05-17 | 2003-08-13 | Elan Drug Delivery Limited | Microparticles and their use in wound therapy |
GB9610341D0 (en) | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5766520A (en) | 1996-07-15 | 1998-06-16 | Universal Preservation Technologies, Inc. | Preservation by foam formation |
US5698537A (en) | 1996-06-18 | 1997-12-16 | Clarion Pharmaceuticals Inc. | Method of lowering the viscosity of mucus |
TW497974B (en) | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
GB2330532A (en) | 1996-07-10 | 1999-04-28 | Danbiosyst Uk | Compositions suitable for delivery of genes to epithelial cells |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
US5853740A (en) | 1996-08-07 | 1998-12-29 | Abbott Laboratories | Delivery system for pharmaceutical agents encapsulated with oils |
KR100542816B1 (en) | 1996-08-22 | 2006-01-11 | 알티피 파마 코포레이션 | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
US5729948A (en) | 1996-08-29 | 1998-03-24 | Levy; Tzadok | Apparatus and method for rigidly joining construction elements to one another |
ID18137A (en) | 1996-08-29 | 1998-03-05 | Schering Corp | AEROSOL MOMETASON FUROAT FREE FORMATION CHLOROFLUOROKARBON |
US6017310A (en) | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
GB9620187D0 (en) | 1996-09-27 | 1996-11-13 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
GB9621825D0 (en) | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
SE507658C2 (en) | 1996-12-02 | 1998-06-29 | Bofors Ab | Ways to store, transport and deliver ammunition to artillery pieces as well as a transport vehicle designed accordingly |
US6468782B1 (en) | 1996-12-05 | 2002-10-22 | Quadrant Healthcare (Uk) Limited | Methods of preserving prokaryotic cells and compositions obtained thereby |
US5875716A (en) | 1996-12-05 | 1999-03-02 | Markem Corporation | Rotating ink cup |
US6068600A (en) | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
US6517860B1 (en) | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
AU5806998A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
GB9700624D0 (en) | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
DE69732306T2 (en) * | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | PREPARATION OF PARTICLE MEDICINES FOR INHALATION |
ES2195317T3 (en) | 1997-01-30 | 2003-12-01 | Chiron Corp | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES. |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
US5829435A (en) | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
GB9705588D0 (en) | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
US5843193A (en) | 1997-03-18 | 1998-12-01 | Revlon Consumer Products Corporation | Hair dye compositions and process |
US5898028A (en) | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
IL132886A0 (en) | 1997-05-20 | 2001-03-19 | Galenica Pharmaceuticals Inc | A triterpene saponin-lipophile conjugate a pharmaceutical composition containing the same and a vaccine containing the same |
DK0991702T3 (en) | 1997-06-20 | 2001-12-03 | Coloplast As | Hydrophilic coating |
US20030035778A1 (en) | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
FR2766706B1 (en) | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | STABLE PARTICULATE COMPLEXES OF NEUTRAL OR NEGATIVE GLOBAL LOAD OF MULTILAMELLAR STRUCTURE COMPOSED OF AT LEAST ONE BIOLOGICALLY ACTIVE GLOBALLY ANIONIC SUBSTANCE AND A CATIONIC COMPONENT, THEIR PREPARATION AND USE |
US6048546A (en) | 1997-07-31 | 2000-04-11 | Sandia Corporation | Immobilized lipid-bilayer materials |
US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
EP1009386B1 (en) | 1997-08-29 | 2005-08-31 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
WO1999016420A1 (en) | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in nebulizers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
AU750567B2 (en) | 1997-09-29 | 2002-07-25 | Novartis Ag | Stabilized preparations for use in nebulizers |
US6423334B1 (en) | 1997-10-01 | 2002-07-23 | Elan Corporation, Plc | Composition and method for enhancing transport across gastrointestinal tract cell layers |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
CN100383671C (en) * | 1997-12-19 | 2008-04-23 | 富士施乐株式会社 | Imaging method |
EP1037629B1 (en) | 1997-12-19 | 2004-10-27 | Janssen Pharmaceutica N.V. | Combination of a retinoic acid metabolism blocking agent and a tocophereol |
GB9727102D0 (en) | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
US6086376A (en) | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
CA2322435A1 (en) | 1998-03-02 | 1999-09-10 | Applied Vaccine Technologies Corp. | Methods and devices for modulating the immune response |
GB9805102D0 (en) | 1998-03-10 | 1998-05-06 | Ciba Geigy Ag | Device |
YU56600A (en) | 1998-03-16 | 2004-03-12 | Inhale Therapeutic Systems Inc. | Device for delivering an active agent to the lung of a human patient |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
DE69907456T2 (en) | 1998-06-24 | 2004-03-25 | Advanced Inhalation Research, Inc., Cambridge | LARGE POROUS PARTICLES SURROUNDERED BY AN INHALER |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
US6165597A (en) | 1998-08-12 | 2000-12-26 | Swagelok Company | Selective case hardening processes at low temperature |
US6334182B2 (en) | 1998-08-18 | 2001-12-25 | Intel Corp | Scheduling operations using a dependency matrix |
DE69936386T2 (en) | 1998-08-25 | 2008-03-06 | Advanced Inhalation Research, Inc., Cambridge | SPRAY DRIED PROTEIN FORMULATIONS |
UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
JP2002529394A (en) | 1998-11-10 | 2002-09-10 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Therapeutic set containing a pulmonary surfactant composition |
CA2355775A1 (en) | 1998-12-17 | 2000-06-22 | Pathogenesis Corporation | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
US6265384B1 (en) | 1999-01-26 | 2001-07-24 | Dale L. Pearlman | Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents |
GB9906695D0 (en) | 1999-03-24 | 1999-05-19 | Secr Defence | Vaccine composition |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US20020090381A1 (en) | 1999-04-09 | 2002-07-11 | H. Kim Bottomly | System for controlling immune system response to antigen |
US6737066B1 (en) | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
MXPA01012246A (en) | 1999-05-28 | 2002-08-12 | Inhale Therapeutic Syst | Apparatus and method for dispensing metered amount of aerosolized medication. |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6606992B1 (en) | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
CA2383491A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Large porous particles by spray-drying |
WO2001013891A2 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
CA2389652A1 (en) | 1999-10-12 | 2001-04-19 | National Research Council Of Canada | Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte(ctl) responses and protect the vaccinated host against intracellular pathogens and cancer |
DE60044070D1 (en) | 1999-10-29 | 2010-05-06 | Novartis Ag | Dry powder compositions with improved dispersity |
US20010035184A1 (en) | 1999-12-17 | 2001-11-01 | Carlos Schuler | Systems and methods for treating packaged powders |
US20020103165A1 (en) | 2000-02-29 | 2002-08-01 | Alliance Pharmaceutical Corp., | Engineered spray-dried lipid-based microparticles for cellular targeting |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0011807D0 (en) | 2000-05-16 | 2000-07-05 | Quadrant Holdings Cambridge | Formulation for inhalation |
US20020106368A1 (en) | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same |
EP1309312A2 (en) | 2000-08-07 | 2003-05-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6475468B2 (en) | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6804260B2 (en) | 2001-02-16 | 2004-10-12 | Qualcomm, Incorporated | Method for selectively maintaining and applying PPP compression in a wireless communication system |
WO2003002834A1 (en) | 2001-06-29 | 2003-01-09 | Sentry Protection Products, Inc. | Apparatus for protecting a structural column |
JP3620479B2 (en) | 2001-07-31 | 2005-02-16 | 株式会社島津製作所 | Method of ion selection in ion storage device |
US6752893B2 (en) | 2001-09-28 | 2004-06-22 | Gentex Corporation | Rimless spectacles and method for making the same |
US20030096774A1 (en) | 2001-11-21 | 2003-05-22 | Igor Gonda | Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
CN1642524B (en) | 2002-03-12 | 2011-05-18 | 微计量治疗公司 | Site specific delivery of co-administered drugs via inhalation |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
BR0317810A (en) | 2002-12-31 | 2005-11-29 | Nektar Therapeutics | Pharmaceutical formulation and method of manufacturing the same |
FR2853450B1 (en) * | 2003-04-04 | 2006-09-08 | Thales Sa | CONTROL GRID OF AN ELECTRONIC TUBE |
WO2005044226A2 (en) | 2003-11-04 | 2005-05-19 | Nectar Therapeutics | Lipid formulations for spontaneous drug encapsulation |
EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
JP2008503586A (en) | 2004-06-21 | 2008-02-07 | ネクター セラピューティクス | Compositions, methods and systems comprising amphotericin B |
-
2000
- 2000-05-10 US US09/568,818 patent/US7871598B1/en not_active Expired - Fee Related
-
2001
- 2001-05-08 MX MXPA02011003A patent/MXPA02011003A/en active IP Right Grant
- 2001-05-08 JP JP2001581791A patent/JP2003533449A/en not_active Withdrawn
- 2001-05-08 EP EP14181405.3A patent/EP2851067A1/en not_active Withdrawn
- 2001-05-08 WO PCT/US2001/014824 patent/WO2001085137A2/en active Application Filing
- 2001-05-08 EP EP01933194A patent/EP1282405A2/en not_active Withdrawn
- 2001-05-08 CA CA2408464A patent/CA2408464C/en not_active Expired - Lifetime
- 2001-05-08 KR KR1020027015136A patent/KR100845445B1/en active IP Right Grant
- 2001-05-08 KR KR1020087007331A patent/KR20080031532A/en not_active Application Discontinuation
- 2001-05-08 AU AU2001259637A patent/AU2001259637A1/en not_active Abandoned
-
2010
- 2010-12-14 US US12/967,482 patent/US8349294B2/en not_active Expired - Fee Related
-
2012
- 2012-12-06 US US13/707,563 patent/US8877162B2/en not_active Expired - Fee Related
-
2013
- 2013-07-12 JP JP2013147090A patent/JP5952231B2/en not_active Expired - Lifetime
-
2014
- 2014-04-02 US US14/243,639 patent/US9439862B2/en not_active Expired - Lifetime
- 2014-09-05 US US14/478,573 patent/US20140377361A1/en not_active Abandoned
-
2015
- 2015-03-11 LU LU92678C patent/LU92678I2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA02011003A (en) | 2004-08-19 |
JP5952231B2 (en) | 2016-07-13 |
WO2001085137A2 (en) | 2001-11-15 |
US20140377361A1 (en) | 2014-12-25 |
JP2013237681A (en) | 2013-11-28 |
EP2851067A1 (en) | 2015-03-25 |
US8877162B2 (en) | 2014-11-04 |
JP2003533449A (en) | 2003-11-11 |
US9439862B2 (en) | 2016-09-13 |
US7871598B1 (en) | 2011-01-18 |
EP1282405A2 (en) | 2003-02-12 |
US20130095153A1 (en) | 2013-04-18 |
CA2408464C (en) | 2016-01-26 |
KR100845445B1 (en) | 2008-07-10 |
WO2001085137A3 (en) | 2002-04-18 |
CA2408464A1 (en) | 2001-11-15 |
US20140212504A1 (en) | 2014-07-31 |
KR20030038541A (en) | 2003-05-16 |
KR20080031532A (en) | 2008-04-08 |
US8349294B2 (en) | 2013-01-08 |
LU92678I2 (en) | 2015-11-02 |
US20110082076A1 (en) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8877162B2 (en) | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery | |
JP5989750B2 (en) | Pulmonary delivery of fluoroquinolone | |
AU2002242253B2 (en) | Modulation of release from dry powder formulations | |
EP2050437A1 (en) | Improved pharmaceutical dry powder compositions for inhalation. | |
ES2953878T3 (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
CA2478974C (en) | Inhalable sustained therapeutic formulations | |
PT2630954T (en) | Pulmonary delivery for levodopa | |
AU2006220411A1 (en) | Inhalable Sustained Therapeutic Formulations | |
EP3179986B1 (en) | Dry powder formulations for inhalation | |
Tarara et al. | Formulation of dry powders for inhalation comprising high doses of a poorly soluble hydrophobic drug | |
CN107205936B (en) | Composition comprising at least one dry powder obtained by spray drying for increasing the stability of the formulation | |
AU2012261584B2 (en) | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | |
AU2006236049A1 (en) | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | |
Focaroli et al. | The Use of a Three-Fluid Atomising Nozzle in the Production of Spray-Dried | |
EP3203984B1 (en) | Pharmaceutical composition containing budesonide and formoterol. | |
BR112017007142B1 (en) | PHARMACEUTICAL COMPOSITION FOR INHALED USE IN POWDER FORM COMPRISING BUDESONIDE AND FORMOTEROL AND KIT COMPRISING SAID COMPOSITION |